

US009551720B2

(12) United States Patent

Singbartl et al.

(54) URINE BIOMARKERS FOR PREDICTION OF RECOVERY AFTER ACUTE KIDNEY INJURY: PROTEOMICS

- (75) Inventors: Kai Singbartl, Hummelstown, PA (US);
 John A. Kellum, Jr., Pittsburg, PA (US)
- (73) Assignee: University of Pittsburgh—Of the Commonwaelth System of Higher Education, Pittsburgh, PA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 13/981,747
- (22) PCT Filed: Jan. 20, 2012
- (86) PCT No.: PCT/US2012/022028
 § 371 (c)(1),
 (2), (4) Date: Aug. 14, 2013
- (87) PCT Pub. No.: WO2012/102963PCT Pub. Date: Aug. 2, 2012

(65) **Prior Publication Data**

US 2013/0323751 A1 Dec. 5, 2013

Related U.S. Application Data

- (60) Provisional application No. 61/436,364, filed on Jan. 26, 2011.
- (51) Int. Cl. *G01N 33/68* (2006.01)
- (52) U.S. Cl.
 CPC G01N 33/6893 (2013.01); G01N 2800/347 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01)
- (58) Field of Classification Search None See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,480,792 A	A 1/1996	Buechler et al 435/6.16
5,525,524 A	A 6/1996	Buechler et al 436/518
5,571,698 A	A 11/1996	Ladner et al 435/69.7
5,631,171 A	A 5/1997	Sandstrom et al 436/518
5,679,526 A	A 10/1997	Buechler et al 435/7.1
5,824,799 A	A 10/1998	Buechler et al 540/128
5,851,776 A	A 12/1998	Valkirs 435/7.1
5,885,527 A	A 3/1999	Buechler 422/412
5,922,615 A	A 7/1999	Nowakowski et al 436/518
5,939,272 A	A 8/1999	Buechler et al 435/7.1
5,947,124 A	A 9/1999	Buechler et al 128/898
5,955,377 A	A 9/1999	Maul et al 436/518
5,985,579 A	A 11/1999	Buechler et al 435/7.1
6,019,944 A	A 2/2000	Buechler 422/412
6,057,098 A	A 5/2000	Buechler et al 506/18
6,113,855 A	A 9/2000	Buechler 422/412
6,143,576 A	A 11/2000	Buechler 436/518
2007/0154897 A	A1* 7/2007	Yen et al 435/6

(10) Patent No.: US 9,551,720 B2

(45) **Date of Patent:** Jan. 24, 2017

FOREIGN PATENT DOCUMENTS

WO	WO 2010/036342	A2		4/2010
WO	WO 2010/048346		*	4/2010
WO	WO 2011/025917	A1		3/2011
WO	WO 2011/057147		*	5/2011

OTHER PUBLICATIONS

Ali, et al., "Incidence and outcomes in acute kidney injury: a comprehensive population-based study." *J Am Soc Nephrol*, 18(4):1292-1298 (2007).

Augustine, et al., "A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF." *Am J Kidney Dis*, 44(6):1000-1007 (2004).

Bagshaw, et al., "A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients." *Nephrol Dial Transplant*, 23(4):1203-1210 (2008).

Bellomo, et al., "Acute Renal Failure—Definition, Outcome Measures, Animal Models, Fluid Therapy and Information Technology Needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group." *Crit Care*, 8(4):R204-212 (2004).

Bhandari and Turney, "Survivors of acute renal failure who do not recover renal function." *QJM*, 89(6):415-421 (1996).

Charlson, et al., "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation." *J Chronic Dis*, 40(5):373-383 (1987).

Chertow, et al., "Acute kidney injury, mortality, length of stay, and costs in hospitalized patients." *JAm Soc Nephrol*, 16(11):3365-3370 (2005).

Coca, et al., "Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review." *Kidney Int*, 73(9):1008-1016 (2008).

Cwirla, et al., "Peptides on phage: a vast library of peptides for identifying ligands." *Proc Natl Acad Sci U S A*, 87(16):6378-6382 (1990).

Devlin, et al., "Random peptide libraries: a source of specific protein binding molecules." *Science*, 249(4967):404-406 (1990).

Fischer, et al., "A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis." *Intensive Care Med*, 29(7):1043-1051 (2003).

"Gastrointestinal Disorders." in *The Merck Manual of Diagnosis and Therapy* (Beers, et al., Eds.) 17th ed., pp. 221-342, Merck (1999).

(Continued)

Primary Examiner — Suzanne M Noakes

(74) Attorney, Agent, or Firm — Medlen & Carroll, LLP

(57) **ABSTRACT**

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.

8 Claims, 7 Drawing Sheets

(56) **References Cited**

OTHER PUBLICATIONS

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1741-1753) McGraw-Hill Medical, New York (2008a).

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1754-1766) McGraw-Hill Medical, New York (2008b).

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1767-1778) McGraw-Hill Medical, New York (2008c).

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1779-1791) McGraw-Hill Medical, New York (2008d).

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1792-1804) McGraw-Hill Medical, New York (2008e).

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1805-1817) McGraw-Hill Medical, New York (2008f).

George and Neilson, "Disorders of the Kidney and Urinary Tract." in *Harrison's Principles of Internal Medicine, 17th Edition* (Fauci, et al., Eds.) 17th ed., pp. 1741-1830, (pp. 1818-1830) McGraw-Hill Medical, New York (2008g).

Herget-Rosenthal, et al., "Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range." *Ann Clin Biochem*, 41(Pt 2):111-118 (2004).

Hirsch, et al., "NGAL is an early predictive biomarker of contrastinduced nephropathy in children." *Pediatr Nephrol*, 22(12):2089-2095 (2007).

Kellum, "Acute kidney injury." Crit Care Med, 36(4 Suppl):S141-145 (2008).

Knaus, et al., "The Apache III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults." *Chest*, 100(6):1619-1636 (1991).

Lassnigg, et al., "Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study." *J Am Soc Nephrol*, 15(6):1597-1605 (2004).

Levy, et al., "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference." *Crit Care Med*, 31(4):1250-1256 (2003).

Liu and Yang, "Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?" *Kidney Int*, 70(2):238-240 (2006).

Manns, et al., "Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery." *Crit Care Med*, 31(2):449-455 (2003).

McCullough, et al., "Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary." *Rev Cardiovasc Med*, 7(4):177-197 (2006).

Mehta, et al., "A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure." *Kidney Int*, 60(3):1154-1163 (2001).

Mehta, et al., "Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury." *Crit Care*, 11(2):R31 (2007).

Mishra, et al., "Kidney NGAL is a novel early marker of acute injury following transplantation." *Pediatr Nephrol*, 21(6):856-863 (2006).

Nelson and Griswold, "A computer program for calculating antibody affinity constants." *Comput Methods Programs Biomed*, 27(1):65-68 (1988). Palevsky, et al., "Intensity of renal support in critically ill patients with acute kidney injury." *N Engl J Med*, 359(1):7-20 (2008).

Parikh, et al., "Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit." *JAm Soc Nephrol*, 16(10):3046-3052 (2005).

Parikh, et al., "Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery." *Kidney Int*, 70(1):199-203 (2006).

Pecoits-Filho, et al., "Associations between circulating inflammatory markers and residual renal function in CRF patients." *Am J Kidney Dis*, 41(6):1212-1218 (2003).

Praught and Shlipak, "Are small changes in serum creatinine an important risk factor?" *Curr Opin Nephrol Hypertens*, 14(3):265-270 (2005).

Ricci, et al., "The RIFLE criteria and mortality in acute kidney injury: A systematic review." *Kidney Int*, 73(5):538-546 (2008).

Ronco, et al., "Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin." *Semin Nephrol*, 27(3):352-362 (2007).

Scott and Smith, "Searching for peptide ligands with an epitope library." *Science*, 249(4967):386-390 (1990).

Supavekin, et al., "Differential gene expression following early renal ischemia/reperfusion." *Kidney Int*, 63(5):1714-1724 (2003). Thakar, et al., "A clinical score to predict acute renal failure after

cardiac surgery." J Am Soc Nephrol, 16(1):162-168 (2005). Uchino, et al., "Acute renal failure in critically ill patients: a

multinational, multicenter study." JAMA, 294(7):813-818 (2005).

Uchino, et al., "Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study." *Crit Care Med*, 37(9):2576-2582 (2009).

Uehlinger, et al., "Comparison of continuous and intermittent renal replacement therapy for acute renal failure." *Nephrol Dial Transplant*, 20(8):1630-1637 (2005).

van Erp, et al., "Application of a sol particle immunoassay to the determination of affinity constants of monoclonal antibodies." *J Immunoassay*, 12(3):425-443 (1991).

Vincent, et al., "The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine." *Intensive Care Med*, 22(7):707-710 (1996).

Ward, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*." *Nature*, 341(6242):544-546 (1989).

Watrick and Morrison, "Kidney Disease." in *Current Medical Diagnosis and Treatment 2008* (McPhee, et al., Eds.) 47 ed., pp. 785-815 (2008a).

Watrick and Morrison, "Kidney Disease." in *Current Medical Diagnosis and Treatment 2008* (McPhee, et al., Eds.) 47 ed., pp. 785-815 (2008b).

Wilson, et al., "Simplified conjugation chemistry for coupling peptides to F(ab') fragments: autologous red cell agglutination assay for HIV-1 antibodies." *J Immunol Methods*, 175(2):267-273 (1994).

Yarmush, et al., "Coupling of antibody-binding fragments to solidphase supports: site-directed binding of F(ab')2 fragments." J Biochem Biophys Methods, 25(4):285-297 (1992).

Zappitelli, et al., "Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study." *Crit Care*, 11(4):R84 (2007). ISR PCT US2012/022028.

Kwon, et al., "Simultaneous monitoring of multiple urinary cytokines may predict renal and patient outcome in ischemic AKI." *Ren Fail*, 32(6):699-708 (2010).

Kitamura, et al., "IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells." *Immunity*, 23(5):491-502 (2005).

Koyner, et al., "Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery." *Kidney Int*, 8:1059-1069 (2008).

Matsumoto, et al., "Hepatocyte growth factor in renal regeneration, renal disease and potential therapeutics." *Curr Opin Nephrol Hypertens*, 9(4):395-402 (2000).

(56) **References Cited**

OTHER PUBLICATIONS

Nejat, et al., "Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit." *Crit Care*, 14(3):R85 (2010).

Pencina, et al., "Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond." *Stat Med*, 27(2):157-172; discussion 207-112 (2008).

Stevens, et al., "Factors other than glomerular filtration rate affect serum cystatin C levels." *Kidney Int*, 75(6):652-660 (2009).

Taman, et al., "Increase urinary hepatocyte growth factor excretion in human acute renal failure." *Clin Nephrol*, 48(4):241-245 (1997). Uchida and Gotoh, "Measurement of cystatin-C and creatinine in urine." *Clin Chim Acta*, 323(1-2):121-128 (2002). Vijayan, et al., "Hepatocyte growth factor inhibits apoptosis after

Vijayan, et al., "Hepatocyte growth factor inhibits apoptosis after ischemic renal injury in rats." *Am J Kidney Dis*, 38(2):274-278 (2001).

* cited by examiner



Figure 1

Arthur A vs B

UI	AVS	в						
		,		. .				
	9.5	۽		2 4	Pepfides	Spectra	Coverage	, Protein
			6	0	7	29	0.51	beta globin [Homo sepiens]
*******	**************************************			3	13	20	0,279	catelese (Humo sapiens)
····\$		jana mafan T			3	5	NaN	myoglobin (Houzo sapiena); myoglobin [Houzo sapiena]; myoglobin (Houzo sapiena)
			6 6	-	12	36	RaN	alpha 'i globia (Homo sapiene); sloha 2 globin (Homo sapiene)
******				1	12	14	0,297	Remover as [Homo saperis]
		1			24	-96	26926 21-24	serve processes contents, cases A, mentaer 1 (Horns separately) serve processes instance, case A, mentaer 1 (
		numho			е 45	755	392423 (5 3 2 2 2 3	survey a construction for the strain of the second strain a production (stored as press), insist a pressure a p
					¢	*6	Mak	TO it a referent to a second of the second of the second s
		·····	Ø		ŝ	7	0.396	brain abundani, menderane staabed alenal protein 1 Biorno aabenal
	majana	i-			5	£	NaM	supertidase 1 [Home sapiens]; dipentidase 1 [Home sapiens]
		, in the second		de como marca more	44	37	6.0758	fibronectin f leatons 5 preproprotein (Homo sapiens)
*****	~ \$~\$ ~\$	·····			10	25	0.293	angiziani ngan preproprisi ni tiomo sapianaj
			.,		39	69	0,301	complement component 3 precursor (Homo septens)
		·····			13	28	Naki	carbonic anhydrawe i [Homo sapiens]; carbonic anhydrase i [Homo sapiena]; carbonic anhydrase i [Homo sapi
			a da di badi da di man basi pang	1 1	25	50	Nelli	uromodiulin precursor (Home suplens); uromodulin precursor (Home suplens)
		an a		in a second second	5 6	18	0.0239	neperan sunate proteogy can 2 (Norto sagilens)
					и 7	14 14	na 224 Kahi	arrin Hinnei nanjangle arrin Hinnen asnja nal
	Ì		•ŏ		3	4	9.90%	della sinder France sante nel
-	i -	m		-	14	27	0.221	fileinean, beis cheis prepropretain litere sablensi
			· •		5	9	0.109	moesin (Homo septens)
		.		4	12	22	8.2%	transferrin (Home septens)
	~~	ļ4		•	4	S	NaN	secreted phrosphoprotein f lectorm o (Homo aspiens); secreted phrosphoprotein i indum a Homo saplens); a
3570904	@@-				8	14	0.213	pancreatic anylana sipha 2A precursor [Homo sapisns]
	ananojanananov. Mar		÷@		3	5	0.129	anexis A2 isotom 1 (Homo sspiras)
			Contraction of the second	1	5	5	0.104	complement component 4 binding protein, siplin chain precursor [Homo sapiens]
			6. <i>1</i> 9		65	258	9.744	algumm proprotein promo sapensa
			* 35 *		97 97	23	0.153	appenning ground racion receptor pathway subgrants o [norm) septens;
					25	Sac Sa	6.1.65	aproximation is present and provide and provide and provide and a second s
Market root					2	ž	0.0295	aphanenwaln phospholic states 1, and is assomed isoform 1 procursor filomo sanisasi
*****			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		3	4	0.224	protesseme beta 2 subunit [Hemo sapiena]
			o-@o		9	招	NaN	manganese superoxide dismutase isoform A precursor [Homo sepiens]; manganese superoxide dismutase iso
*****	~~~~Q	- and a second	*********	dammer and an and a	6	17	0.49	iransfiyeratis (ilonia sastens)
				4	<u>g</u>	13	NaN	haptoglohin isoform 1 proproprotein (Homo sepiene); huptoglohin isoform 2 preproprotein (Homo sapiene)
and last	n og ja man og ja General og som	e i	Quanana,	4	2	2	9,0327	fibulie 1 isolerm D [Homo sapiens]
		ş	28	el	5	5	0.194	serve (or cystence) proteinase influctor, clade C (antithrombin), mender i piomo sapienaj
			- Q		a 5	3 51	14.3488 -01.443	ny pour cuta proven a live 140 and 170 mm supports; Any file Real proven a live 140 and 170 mm supports;
	àe	ş)		3		53m36	energy and a second
*******			- @>		a	10	0.319	sector compression of globality is follower assignments account and non-sector preferablem to from the compression account and the follower assignments of the sector and the sector and the sector of the sector account of
		5	****		8	12	Nett	complement component i inhibitor resource riteme sequenci: complement component i inhibitor presurer il
			· · · · · · · · · · · · · · · · · · ·	¢	3	3	解剖剂	chromatin madifying protein 5 [Houro sapiens]
			@®	5	4	5	0.146	viscuolar protein sorting factor 42 (Homo saplans)
	}		- Q- >		9	15	0.158	prominin t (Henne septensi
		ø			8	7	0.0353	aipha 3 type VI collagen isolorm 1 precursor [Honro saplona]
****		rannangi Filo			10	13	Nan	actin, ganasia i propentice (Homo sepisna); beta actin (Homo sepisna)
		S			2	3	0.0388	sonne carrier ramuy a (sociami giscosse ociransporter), member 12 (Homo sapiens)
					4	5	NaN	annezin A11 (nomo sapiens); ennezin A11 (Homo sapiens); ennezin A11 (Homo sapiens)
		a_⊺	age and a second	Jammana	e 2		95, 541 A 2013	one uneane aneany any proversit 40 (702000 September) fattu ardit foliodine menjala 2. artizerrata filizare azakenat
					2	2	NaM	may man samany process 4, mapooput prents septence; perfessions sinks 3 submit benform 1 Blenn samisarity medescenes sinks 3 submit isolarm 9 Blenn seriesal
******	ww.ing	0	,	-	5	8	NaN	paisoin isolom a precursor filomo aspisnal; oziacin koform k (Homo sapiens); zelazin izviorm o Homo as
	i		- ∂ -→		12	20	0.192	programmed cell death 8 interaction protein [Formo septens]
·····	····	8- i	p	- i	5	8	0.0964	fensique a motorgrania in sicoro a subiene i
~~~~		~~~~÷	****		16	66	£.634	terilin, fight potpeptide (Homo sapens)
	สาราสุราสาราสารา	+	*@*	4	19	57	0.359	galeatin 3 binding protein [Homo sepiens]
		<b>@</b>	\$	·	3	4	0.276	pepikiogiyoan recognition protein 1 [Homo sapiane]
					5	12	Naiš	ubiquitin and ribosemal protein 527a precursor (Homo supiens); ubiquitin and ribosomel pretein 527a precurs
~~~~		Ø.,			3	8	0.282	hypothetical protein LOC169693 (Homo sapians)
******	*****	nn@iriji		-	뀾	3	0.0921	CD9 antigen (Homo asplana)
enante		188-1-1-			2	2	0,847	solute carrier family 5 (socient glucose cotransporter), member 10 isolorm 2 [Homo sepiens]
	•	9\$	- <u>-</u>	Qanana ana ina ina ina ina ina ina ina in	2	2	NaN	(analque omoth) à moloei 81 mixen gairines ((eneique oracit) e moloei 81 mixen gaitnes
				*i	2	4	Nafi	syntenin isotom i [Hamo sapiens]; syntenin isotom i [Hamo saplens]
		See.	63	~ 6.	25	湖	0.268	gananyi ananpepunase (aninopepiloso A) [Homo sapiensi
		~~.xpb	- CAR	od	z	4	12,00045	Researce transcories caused buoreur (e buoreur) d bolàbeline frique asheuzi

Figure 2

0.25	0.5	1	2 4	Mar - 1944		^	
			4	*epnces	Spears	Laverage	s Hrussen
Immon	and a second second			2	2	558H	ay non-car i parcursor promo aspensi; syntaecan i precursor (Homo sapans)
Juna		i à +		3	4	w.w.ez NoM	sagawa na prantici zapantati ganaaya Wi isriana 2 Manna sanlana'i sanaa la Wi isriana 1 Misan sanlana'
from		garan ana	i	-10	14	BBARI	าสองสัตร์ 2 ต่างสรามสราม 2 (การการราชสรามสรามสุขายสรามสาย 1 (การการการ 1 (การการการการการการการการการการการการก การการการการการการการการการการการการการก
		i - 0 4	jj.	2	3	0.66.67	narowa (rozza angraza) maning malaning maning fi narisin di narisin di narisin i dan sanat di na sanat di sana sanina.
		÷ 0 +	÷	â	ã	NaN	general measure and a subming present or presently against it tong search present comparison in the second se
			÷	g	11	0.172	provincent liferent i levente actional
{	······		·	2	4	Nati	applies carries family 5 (addes insummers), merchan 8 lifering contenal
\$			¢i	2	2	NeN	ras homeles care family, member 2 mercerar Blone assignations have been family member 2 mercerary bloc
	······		÷	8	10	0.0812	complement lactor H lactorm a precursor Blama aspients
		\$	÷	7	9	0.234	Notilita 1 (Romo sapiens)
		• • •	~~~~~	2	3	0.0841	WHE protein (Homo septens)
}		1 Q *	1	3	3	0.0833	putative MAPK activating pretein PM28 [Homo sapiens]
		¢~	· · · · · · · · · · · · · · · · · · ·	8	16	6.238	Notifin 2 [Homo aspiens]
3		Secondana		15	29	0.456	cathepsin C preproposal Home sapers
1	······································	- 195	i -	2	3	0.358	hypothetical protein 1.0C58627 [Homo saplens]
1	in the	. Mar. 10.	1	3	3	Ð.141	annexin 5 [Homo sachens]
-		1. B		-35	3 5	0.283	the second s
	- 12	: NGF "**		*	2 *5	FFREE Bilwee	unius sound press capers; constant sources a from sames;
ļ	- *	10-0-	5 	2	305	19829£ \$5\$5	annan ann an mar martair ag tharmart i bharna ann ann an thiùchan an th' an tar tar a th' ann a' th' ann a' the
		i	r Francisco med	2	e 12	19.005 6.3.40	non menerut syne na mananit i footise miliintsi, een internet cych al isonitti i foitse siipintsi Mananit matain cardina 76 instarm (Llama saninad
		i		ž	3	8.84%	nannanna prantan ann an ga da gabalaisi i fabalaisi ka fabalain balanna nandanan. Mannannaisi ka al'ada a'iada 1821 maandaan i ananannan liinana nandanan.
		1ō -		a.	7	6.224	non-nervening manny many states in the mess contenest of provident of provident of providents
	a			à	ŝ	0.241	complement factor i presenter Home santana?
ļ		- joo		11	17	0.247	souvermer recentor class B. member 2 Home sadensi
ļ	·····		÷i	8	15	Nahi	prolyleatboxypeptidase isolarm 'i preproprotein Bloma papiensi; prolyleatboxypeptidase isolarm ? mammentais n
		.}.@	*****	2	3	0.078	amerile [Piomo sapiane]
	@		-	2	2	0.9440	immunogiobalin superfamily, member 8 (Homo sapiens)
	·····	in Secondaria	-	3	5	0.66833	Fo hagmani of IgG binding protein [itemo saplens]
		· @ ····· *·	ł	2	3	與a對	hypothetical protein LOC284422 [Homo septena]
şanavna 2	••••••••••••••••••••••••••••••••••••••	*@*~**		3	5	與自由	annexin VI (soform 2 [Homo sapiere]; annexin VI (soform 1 [Homo sapiene]
1		- Participation and a second s	?	9	37	0.425	cystatin C precursor (Homo sepiens)
1		103	1	8	21	0.222	tenety 3 [Homo sepiene]
		: 199 P		2	2	0.278	ty pothelical protein LOCS4418 [Home sepiens]
2		1.00	**************************************	2	2	MaM 0.000	CLEE entryen ientorm 2 promo septens); CD82 antigen ientorm i pierne septens;
1				6	13	0.207	napam A prepropromin (riome sapiens)
Şannan				4	3	6.122 6-142	aux prospenses z, geosonal isolomi i piscaren (itemo sepiens) anolizentetais E anormet (itema content)
Suman		4		ž	ŝ	8.199 No.89	nyonyonyonyon mataka 1788 inakana kalina naninasi kanamankana nasisin 4780 (*
ì					3	Naki	normaningumusta suitertinasissaas isriomi 9 Kinava pariareli maanunismeneinen aite selitetti 1 (1000 SKRISKS) S
		į	į!	2	ŷ	8.0.075	mannalize shhe des 12 menter 1 from aviane 1
ţ				2	2	0.109	internet menthene protein 28 Manus series al
ţ		0	ร้างการการรู้	4	ŝ	0.112	tetraduat 1 (Home series)
	·····		francis	8	23	0.344	apoliocontein D mesurar Homo aniens)
	÷		fransanan	8	18	0.417	vicuatin isolann a Hamo appiens;
		¢		3	3	0.0937	kiningen t isolenn 2[Fieme sepiens]
Provinces	****************	@ o	· ·······	8	4	0.101	guarine nucleotitis binding protein (G protein), siphs inhibiting activity polyseptide 2 (Hamo sectional
	·····	ي. بر بيند مي	for the second second	39	112	0.657	olfactomedin 4 precursor [Homo septens]
	·····	- Q	\$ manual	3	3	0.150	brain creatine kinase (Hamo sapiene)
}		1 🧐 – ° –		3	4	转函数	chromatin modifying protain 24 [Homo sapiens]; chromatin modifying protain 24 [Homo sepiens]
304. 11. 10. 17 5		6 fr. 1. 1. 1. 19 varian 19 va 19 varian 19	gramma se se se ser constante de	2	2	0.6829	solute carrier family 4, sodium bicarbonete colvensporter, member 4 isotorm 2 [Romo aspiene]
}			graamerica and	20	27	6.232	ceruloplaamin precursor (Homo aapiens)
		·	1916-0-16-16-16-08-08-18-18-18-18-18-18-18-18-18-18-18-18-18	4	4	0.186	giverophosphodiselar phosphodiestense domain containing 3 [Homo aspisna]
1	\$	100	1	4	4	14,67,67	givouruniciese, bela (Homo sapiene)
	and the second	1.63		2	2	¥.0329	solute corrier tamily 4, anton exchanger, member 1 [Homo sapiene]
han		1997 - 1997 Li		2	2	Pease	arysummase A teororm a precursor [Homo saplans]; arylaullatase A leaform a precursor [Homo pepiens]; arylaulla
		10		z	2	4.0542	nelanii u (maini baynens)
Lunnon		1 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000		4	8 19	4.4923	pyrumue arrane, musice isutanti \$2 [Hana septens]
		0 .		3	2	-0.192	ananderanna againe a baabaanig gganna anagerag mangeranna againe a sambaa againe gganna anagerag
	·····	10 · ·		5	ac. 港	10.07.1%	personanan apara sananan paning paning paning paning
j		şiş	**************************************	4	ŝ	0.0464	and also consider families & many land 10 filtrane mania and
Junion				2	2	MaN	datar sound in terms in manufat in controling and leaders I narrience Blance contained
				54	111	0,483	mentione simile antipopenticiste precision filmen anticaet
-	·····	10 v-	-{	3	3	0,106	tali interacting protein fiforng sagisasi
ļ	@	j		2	2	0.0593	aryisulfatase F precursor [Homo saplens]

Figure 2 (cont'd)

0.25	0.5	ŧ	2 4				
<u> </u>			e ngan manang	Peptides :	Specia	Coverage	s Protein
<u> </u>		A 102 A		16	25	0.234	fensione sources fension security to the security of the secur
				5	13	Haft	calingsin C inclore a preproprotale [Homo septens]
				2	*	13,744	pressure service press [House each del
				4	4	18.144	vacuolas promits sorting factor 4A (Plume sagianas)
				4	2	0,09990	unismensione protein 192 (Horno Septens)
				7		0.00 0.000	The man from the present work (reaching and particular to the present of the pres
j				*	2	33mbi	
-				2	3	A DASS	ungen und aussent presente annue i e sectemente afrant (rount) supporter present properti à l'annue societant se
þ		· · · · · · · · · · · · · · · · · · ·		2	ŝ	NaM	DEFINICATELY SERVICES AND A DEPENDENT AND A DEPENDENT A LANGE AND A DEPENDENT
}		····· e Kg	un den en en en en en el el el el el en en en el el el el en en en el el el en en en el el el en en en en el e	a	18	NoN	CD53 antitacti isolarm B litramo ancient: CD53 antiques isolares 4 litrana antiana?
		~~~ (Q ~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		2	3	0.061	MARVEL domain containing 3 isolores 1 Homo sanisons)
have		¢		4	s	0.0648	siziki [Homo saziens]
÷	mmmm uniform	~~~ <u>~</u> ``@~~~~~q	hud and an	2	2	0.0532	tubulin, alpha ta piamo sapionaj
\$mme			•	8	14	0.212	FIZ domain containing t [Homo septens]
	mennennen (	* ~	-	2	13	NaN	target of mybri isoform i [Homo sepiens]; target of mybri isoform 2 [Homo sepiens]
-				Ž	3	0.241	oyata 1 [Humo sepiena]
-		- 199 · · ·		2	8	0,135	CNEP dipopuldase 2 [Homo espiene]
£				2	2	REN	syntaxa nietora i nietora i nietora galional nivzinya ganałą o motol i zwiota i z nietora pilona nietora g
i				2	x	0.120	maina melakoprose mase / preproprete in [trano septens]
÷				**	40	0.0000	
		0		14 14	10	0.257 0.482	inclusion preciment precime sectors and the sector of the
		à	unfarma marcana d	ä		0.087	annavarysaan i freene a waarnay illaan a ankan i
- j		s		4	4	Nati	new product a second a production of the second second reaction of the second section is a second section benef
h				5	7	0.184	encise i Hono selensi
÷			mpournment	2	2	han	hypothetical protein LOCE4355 isoform 2 il-tamo sapienal: hypothetical protein LCECA355 indown 1 litemo saciens
<b> </b>		·····		2	2	0.0563	urate anion exchanger i isoform a Homo sanisnel
laur	romen consideration			3	4	0.100	by pothetical protein LOC28970 [Homo sepiens]
	¢¢	)		2	2	摇辫	chlaride channel 7 isofarm b jHomo saplensj, chlaride shannel 7 isoform s [Homo saplens]
				5	7	0.058	solute carrier family 34 (sodium phosphats), member 2 [Homo aspices]
				3	4	0.110	vscuolat H+AIPase B2 [Homo sapiens]
1	1			5	1	0.0745	angiotecom i converting enzyme 2 precuraor [Planne aspiens]
hereau					30	0.149	
		-o		*	а 4	14. 8734 8882	
		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		2	2	0.0763	Arras, ir vangerning, geovenin er skonni i novini i Aroni Sperioj, Arras, ir unepping, gossing, i
ļ		o		2	4	0.065	dinentidri paritava 7 menentide formati antenati attenung attenung paritaritus 2 fremu sapatari
ţ		\$		3	a	Nati	kerstis 10 [Home sapless]
	·····	······································		2	2	NaĦ	villin t [Homa sagiena]
}		- \$ _ \$- \$-		2	3	0.0439	skiewyde dewydroganase 1A1 [Homo sapiens]
20000		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		4	5	0.151	phusphoghycerate kinase 1 [Homo saplene]
	1 1	- A -		12	21	NaN	heat short 70kDs protein 1A [Homo saplens]; hast shock 70kDs protein 18 [Homo saplens]
1				2	3	NaN	hypothetikal protein LOC126321 Isoform b [Hamo sapiene]; hypothetical protein LOC126321 isoform c [Flome sapie
1		an a		2	2	0.6238	mannesidase, alpha, class 2B, member 2 [Hano sapiens]
June .				2	2 19	26329 A 4.4*	uur 4 assugen iseionna arionnö sepisensi; tub/4 antigen isotorm 6 [Homo sapisens]; CD74 antigen isotorm k [Homo s
į.	on manafaran			3	۰ <i>ه</i> . ۲	A 247	entralis di Brance et l'avarez gell'entre: Investi de l'Investe anter esti esti esti esti esti esti esti esti
į				ž	õ	0.025%	aprovense z general segurativa paratelari anticidenciali i compatibili autorativa indentiti i antananone (Linean socia-se)
j				2	ã	6,105	national sectorizes 1 Homo assiend
		·····		10	18	0.26	sodium/hydrogaa syntameer regulatory factor i Henne sanismal
		* 🔅 *		2	2	NaM	argininosuscinate synthetase 1 [Hone appletes]; anthinosuccinate synthetase 1 [Home sentend]
ş		• • • • • • • • • • • • • • • • • • •		2	3	和时间	spinster homolog 1 isotorm 1 Flomo sapiens), spinster homolog 1 isotorm 1 [Homo sapiens]
ţ	าาราค พระกำสุดเหต	**************************************	migamenter (2	2	Ø.1	superonkie disnuitase 3. autoaceliular procusar [Hamo saplens]
		·		4	4	0.0971	havosaminidase B preproprotein (Henro sapiens)
				2	3	0.869	discupted in sensi carcinoms 2 [House sapiene]
	àààààà			4	7	0.0501	unas complex locus XI.as (Homo septens)
				2	2	U.42232	A surses (PHA) suctor protein 12 isoform 2 [itomo septens]
ļ		a		*	3	292896 0-4777	erosonarcono i precursor (mono sapiens)
ļ				4	2	0.111	Here was an and the advertising on the first Here and Andre advertising and the advertising and the advertising
-				4	77 A	0.132	Incomparison providently prices of SERIE ORIFICIAL Andrew 17 Elements and and a second s
į				4	13	Nak	BRENCTED: heathalinal province Repaire against
Serve		~~~ ġ ~~~~	mp-mmmm_	2	4	0,0766	acchula filoma saniensi
			-+	8	9	0.225	ectonucleotide pyraphysionershearshodisetaras 5 Home seatenet
		· o		2	4	0.0857	ring tinger protein 167 [Rumo septens]
-		····\$··Q··\$····		9	12	0.483	RAB7, member RAS ancogene family Homo saplenaj

Figure 2 (cont'd)

0.25	9	5	1 .	2 4				- Bunded a
					PEQUARES -	ocecas	00464938	r Protein
ĝana	ranamarara	farana 🕸 🗠 🗠		สุขามาระบาท	4	đ	¥9时	perrylcysteine cuidase 1 [Hamo sapiens]
{			Q	farmanan	12	17	6. 183	galectosidase, beta 1 leolorm a preproprotein [Hemo sepiens]
à		ļ	Q-a	÷{	18	36	0.302	heat shock 70kDs protein 8 isoform 1 (Humo septens)
ļ			Q	fa an	2	3	9.210	MAPK newfald proken 1 (Hanno saplens)
		·····	Q	·[~·····{	2	2	0.0314	complement factor B preproprotein [Homo sapiens]
fran			\$\$````	<u> </u>	2	2	0.0438	solute carrier family 12 (potassium/chloride transportera), member 9 [Homo sapiene]
ţ			Ø	สู้งานการกระวะกระกรู้	8	5	0.205	glutathione transferase (Homo expience)
ķ		ģ	Q	÷	5	5	0.184	ATPase, H+ transporting, by sosomal 70kD. V1 subunit A, isoform 1 (Homo sapiens)
			¢	4	2	2	0.6886	agusporta 2 [Homo saplens]
£			۰۰۰۰۰۰		4	8	辨a科	eyntaxin 7 [Stomo sapiens]
		÷	<u>ي</u>	4	5	ş	0.209	major histocompatibility complex, class il, DR alpha precursor (Homo saplens)
Į		÷	\$*	1	3	4	科由科	cytosolis phosphosnolpynavais carboxykinasa i [Homo sapions]
÷		÷	Q		4	6	0.217	glutathione penultiase 3 presureor (Homo sapiens)
\$eer.e		+	- Çi	44	4	4	0.0842	transmembrane 7 superfamily member 3 [Homo sapiens]
ş			Q		2	2	残a 随	transmembrane protein 558 isoform i (Home septens); transmembrane protein 558 isoform 2 (Home septens)
ļ		····· Ø	Q		2	2	0.031	nicastrin precessor (Homo saplens)
ş		·······	-@	derror constant	3	3	9.135	carbazymethylanabutenoblase (Hamo saplens)
- france			Q	+	2	3	0.094	major histocompatibility complex, class II, DR beta 3 precursor [Homo saplens]
ş	*****	· · · · · · · · · · · · · · · · · · ·	÷	farmani	2	2	\$.\$988	hypothetisal protein LOC51571 [Homo saplens]

5 05 1 2 4	Peptidas i	špectva	Coverage	Protein
	. ŧ	1	NaN	complement component 4B preproprotein (Homo saplens)
unananantinanantinanantina (m. 🖓 marantinanantina)	ĩ	2	9.0952	vacuatar profein serting 25 (Home explores)
energia en la calencia de la calencia	*	1	0.0219	chloride intracellular channel 6 [Homo saplens]
	3	3	0.0912	vacuator protein serting 378 (Heans septenal
	4	2	0.6115	complement component 44 property relation and the second
	†	2	0.0217	nkiogen 1 precursor [Homo sapisns]
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	1	¥	詞由祥	histone claster 2, H4b (Homo sapiens); histone cluster 2, H4a (Homo sapiens); histone cluster 7, H4i (Homo sapiens
waanaanaa faanaana ahaa baa 🖓 🗤 🗤 🏷 🎆	1	ž	0.122	hypothetical protein LOC91894 (Homo saplens)
	¥	1	0.143	ring finger protein 152 (Homo septens)
ennennennen (* 1997) - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997	٩	Ť	0.0134	ephria receptor EphAt [Flamo sapiena]
	1	1	0.0878	protessons bets 3 subunit Neuro sapisnal
	4	2	RaM	carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase
ana	4	5	Main	CD59 antigen preproproteix [Homo sapiens]; CD59 antigen preproprotein [Homo septens]; CD59 antigen prepropro
	1	3	0.0353	annicoless protein precursor [Homa saplens]
	4	t	0.0404	von Willebrand instor A domain containing 1 isoform 1 [Homo sapiens]
annan an a	4	Ť	0.0272	plauningen (Humo sapiene)
annan an the second	1	2	9.0671	ficolin 2 isoform a precursor (Homo septens)
	t	1	Nati	glycophorin C isoform 2 [Homo sapiens]; glycophorin C isoform 1 [Homo sapiens]
	1	1	0.0175	colleges, type VI, alpha 1 precursor [Homo septens]
	Ť	*	Made	calmodulin 1 [Homo saplans]; calmodulin 3 [Homo saplans]; calmodulin 2 [Homo saplans]
	\$	*	0.069	ros homolog gene family, member G (Homa septem)
	Ť	1	0.0558	vocuolar protoin sorting 370 (Hosto saplens)
	1	5	0.0324	protease, series, t preproprotein (Hamo sapiens)
	Ť	2	0.03	prominin 2 (Homo septens)
	4	2	NoN	nistorgenção Anoquitas (lanaique canali) nistangorgençã Anlaquitas (lanaique amoit) nistorgençençã Anlaquitas
	\$	3	0.0292	radixia (Hamo supiens)
	4	1	0,104	GM2 ganglioside activator precausor (Homo supiens)
	重	1	0.188	eckaryolic translation initiation factor 8 isoform c [Homo supiens]
	Ť	2	NaN	syntenia isoform 3 [Homo capiens]; syntenin isoform 3 [Homo sapiens]
anna an	1	1	0.8423	guanine nucleolide binding protein, alpha z polypeptide [Homo suplens]
aanaa ahaa ahaa ahaa ahaa ahaa ahaa aha	*	ţ	0.0231	cytochrome P459, family 4, aubfamily 4, polypeptide 11 (Homo sapiens)
	4	1	0.0226	paptidoglycan recognition protain 2 precianor (Home sapiens)
······································	1	Ť	释白托	SMAD family member 9 isolom b (Homo septenz); SMAD family member 9 isotom a (Homo septens;
	Ť	2	0.0304	phosphelipid transfer protein isoform a precursor (Homo sapiens)
an a	1	1	6.0341	guanice nucleotide binding protein (G protein) alpha 12 [Homo sapiena]
and the second design of the second sec	4	*	0.0234	antida parries fundin 3. mandar 3 librare annimal

Figure 3

0.25	0.5		1	2	4				
2000000				- franse		Pepfides	Spectra	Coverage	Protein
şmmm		\$\$@		nfamm	,	1	2	NaN	se brook a montesi ta member 3 materia divisa januara akusa januara ka motaal 3 member 2 materia akuse
		Q) 	ipananan 🐯 1946 2	en igen noon o	******	3	8	0,946	GiPase Rabit pione aspisos
					••••••••••	3	8	0.164	transmembrana proban a [riomo sapuens]
	~~ f~		0	¢	è	*	1	MaN	calcium binding protein 39 [Homo sapters]; calcium binding protein 39 (Homo sapiens); calcium binding protein 36
177 - 7 - 18 8-	{©			-		1	ŧ	0.00284	hemicardin 1 [Home sapiens]
			(Q	3-4		*	1	0.0213	[knaiqas sansk] niekong negihne šas mele elektrong
\$0 million	ne ne ne al co		(Q	suje		1	2	0.0246	solute carrier iamily 47, member 1 [Homo sapiens]
	•••••••••	þQ	\$@	•••{•••••		÷	1	9.0728	bliverdin multerase B (flavin reductase (NADPH)) [Homo sapiens]
-	munifi	······	i Grand and	Ø.		\$	1	NaM	protessome alpha 4 subunit isoform 1 [Homo saplens]; protessome alpha 4 subunit isoform 1 [Homo saplena]
		•Q	\$		·····	Ť.	1	NaN	palais, lung and nasal aphibelium associated precursor [Homo sapiens]; palais, lung and nasal epithelium associate
			10 ×	mfrans		*	5	制造制	PREDICTED: similar to hCG1642536 [Home aspiens]; PREDICTED: similar to hCG1642535 [Home sapiens]
		······	10	o	·····	*	1	登/8424	actin, alpha 1, skelskal muscle [Humo aspiens]
horner			0	»	f	1	1	0.0656	RAF28, member of RAS oncogene family (Homo saplens)
}-nn ma				·	man	1	8	0.045	transusembrans BAX inhibitor motif containing 1 (Homo supiens)
		····\$	Q	9-j		\$	18	9.0483	nucolipin 1 (tions septens)
}			<b>.</b>	۰÷		Ť	1	0.0343	annexin N [Homo sapiens]
\$a-			·10 ·····	¢r∳~~~~	unnnarð	1	1	和邮料	diazepam binding inhibitor isoform 2 (Homo sapiens); diazepam binding inhibitor isoform 3 (Homo sapiens); diazep
\$		······@·····	- Qa 0	••• \$		1	2	0.0335	tubudin, stphs 4s [Homo sapiens]
	~~~~	\$Q	Ķ	- Andrewski - A Andrewski - Andrewski - Andr	manual	3	1	0,0203	actute carrier family 1 (neutral author actid transporter), member 5 [Home saplana]
	, mente		-iQ	gi dan me	mmnð	*	1	0.0652	claudin 2 (Homo septens)
}	·····-		Q	*	}	1	1	始a 持	myoleilin iaotomi a jihome sapisus); myoloali nilotomi b jihome sapisus)
		袋-	÷	¢.j		*	1	NaM	visieted in malignant insulation of besteles (aneiges emoil) resources a multical i creature niced in malignest
		general C	¥		······	1	1	0.0234	palactosyloaramidase isolorm a precuraci (Homo sapiens)
	เลาะเริ่ม		- Alba -	od		1	1	NaN	hypothesisal protein LOC55194 (Home supports); PREDICTED: hypothetical protein (Home supjens)
į			Ø			1	3	和制	CD151 antigen [Home explane]; CD151 antigen [Home septens]; CD151 antigen [Home septens]; CD151 antigen [Ho
	·····	o	¥	····\$·····	{	1	2	0.066	RAB2A, member RAS encogene family [Homo septens]
humm	mmmere	Q	- ka	g-f		î	1	0.0132	aciinin, alpha 4 [Homo saplens]
\$ errer 10-10	~~~~	oG	ş			ŧ	4	NaM	tumor differentially expressed protein. I [Homo sepiencs]; tumor differentially expressed protein 1 [Homo sepiencs]
hum		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	0 0	zufanna		1	1	NaN	phasehodiesterses 64 isotorm 2 (Homo saplens); phosphodiesterses 84 isotorm 1 (Homo saplens)
		ø	ģ			4	1	0.0112	SH3 domain and tetratricopeptide repeats 1 (Homo septens)
		¢	¥			4	1	NaM	BH3 interacting domain death aconist isoform 2 fiftomo sepienes; Bit3 interacting domain death aconist isoform 3 F
-		.s	ý			1	15	NeN	ribophorin Il Issform 2 pre-cursor [Homo sapiens]
			ö		ŝ	1	1	0.0637	chromatin modifying protein 4C ifforms assients
į			3			1	1	NaN	sacsin litomo seclensi
		a	\$			1	4	0.0444	iunican ne curar frioma assiersi
Şanararını				Grafinin		4	ŝ	0.0302	chromatis madifying pretein 18 Riomo sapleasi
from	เลื้องการการ	&	ğ	,	·		÷.	Nabi	SHC (Sro homology 2 domain containing) transforming protein 1 isoform 2 Ricese sapleys); SHC (Src homology 2 d
Januar				o.i		÷		Mate	STPase, H+ transporting, hyspacial V0 submit at Homo sociens); ATPase, H+ transporting, hyspacial V0 subunit
						÷	÷	0.0544	192 donain moisés 6 (Kome sagéons)
Junio		e	s			ì	i	0.0192	tetratrisonanticis maast cismain 28 Nonn sacional
			G	;		÷	2	0.0620	ervatellin, aloha B [Hama sonianzi]
						:	÷	0.66775	the production of a property strategy approaches and the production of the productio
, 6			ä			÷		51 8/30C	Des (Mon49) have a schlowick (Consultant Schore Schlore)
			100			;	*	的社社	and property interesting accounting of interest of product approximate
harmon				min		т Ф	1 1	10.73 10.73	anonangaran, many antitutes i justagroup (1) inter angents; discharge maintenan at disconcernes (2) have angents attention insintenance of also many at them are
1			20	a in		÷		0.804	antenna menanena vi dennovarimo e promi sepretaj, su denna menarenene vi dendedatado e (1000 depe
		energia a como	- 200 - 200	an in the second		*	*	16 (17) OZ	enger-unies constanteness is evaluate a filteren estatenti
2		÷				*		الاستىتىنىيە ئىلىرىلىغ	energy warrant and the second state of the second and the second se
-				aulum		*	2	A DAMAS	TTELEFOLTELES ANGENERATION OF DESIGNAL (F1993) COLUMNAL Environmental of Element manifesterel
i in the second se	1		29 43	a.l		*	5 -6	0.0445	nanada within and and and
ž	· · · · · · · · · · · · · · · · · · ·		200	n		1	8 ~	4.4459T	energi seresi na sa kananan seregiaranan Kanan da kanan mananan dari kanan kanan kanan da manan da manangkan da kanaharana da Katanana manakaman.
1						1	2	0.0775	ness suura proven svalas agna (Gradans), Cass a normaer laskan i (Tomus Samens)
2	n. renennje	a				1	1	認識	nad (A. Menney The Suncessing Ranky Bound 1 (1078) Someric Racts, Render Ras Choogene Binny Marto So Deconfector Jones & NOSOBOLOS , a wild history contents
ş			29			1	2	24 B 74	* TREASE FREED, AND INCOME WE IN CARD WE & DISCHART (TURNE) COMPARISON AND AND AND AND AND AND AND AND AND AN
	versionside		~}£``````	stade and		1	1	Main	elmanyoris d'analissis initiation factor a la canada a la canad
1			1994	, magana	1010	4	3	6,149	HILL IN THE REAL BOARD STRATE I HIGH SCHOOL STRATE
-	างการการสูง		and the second s	magana	*********	1	Ŧ	New	narosaminalase A prepapatela (Hono sepiens)
şern men				50j		1	1	0.0491	berseuenni recenii i fuone schierel
- Janaar		-Ø	\$*****	e esta esta esta esta esta esta esta est		\$	Ť	0.60904	i zinc linger protein 242 [Homo sapiens]
ş			÷			1	\$	0.9196	akeletui musuke weeptor tyrosina kiaasa (Romo napiena)
******	••••••••••••••••••••••••••••••••••••••	8	· · · · · · · · · · · · · · · · · · ·	*		*	1	NeN	apanta tentera 2 (Hamo sapiene); spestis isolom 1 (Homo saplene)
ş	*****	Q	· @ · · · •			1	3	1.17 <i>4</i> 8	allografi avlianmatory factor i isoform i [Homo saplens]
Į		·····	· @ · · · · · · ·	şç		1	1	0,0539	nunofinate aboophoribosy itansiarese [itomo sapiens]
	mmm	·····	÷+			1	1	Май	transmembrane protein 1864 [Homo saplens]; PREDICTED: similar to Transmembrane protein 1864 [Homo saplens
		······	· 🔂 · · · · · · · ·	\$		1	1	0.962	unopiskin 14 [Homo anoiens]
framm			Q			1	1	0,075	secretary carrier membrane protein 3 leoform 1 [Fiomo saplens]
þ	man		· () · · · · ·	ganfaan		1	Ť	0,225	guarine nucleolide binding protein (G protein), gamma 2 [House saplens]
<u>}</u>			@»	èn fin		\$	Ť	0.0475	sorbital dehydrogenese [Homo sapiens]

Figure 3 (cont'd)

	9.5 	* 	2 4	Participa	Searcha	Cavacacia	Potein
		; j		1	-	0.0258	nator facilitator superfamily domain containing 1 [Humo saniens]
					1	0.110	nuclear transport factor 2 litomo sopiensi
	- han - g g	j		i	4	0.00515	nuckoperin MickDa (Homo sepiens)
		ý	สุดสารางอาการ	3	1	0.0323	hypothetical protein LOC54978 [Homo saplens]
		à		1	1	0.097	adanine phospharibasyltransferase isoform b [forms saplens]
		à		1	\$	0.0811	iyaazyme precursor (Henne sapleas)
		à		ŧ	-\$	0.0779	NAD(P)H dehydrogenese, quinone 2 [Homa sapiens]
	-		-	ŧ	-1	9.122	system 8 (Romo septens)
*****		Q		*	1	0.0522	hiossphosphate isomerase 1 [Homo saplene]
	an faces an age	Q		1	3	6.0676	phospholipid scrambias 3 Homo ampienzi
		ġ		\$	1	0.0233	plasma glutamate carbony peptidase (Homo aspiena)
	mprostan.	<u>چ</u>	nfaranna an	1	ŧ	NeM	bone marrow atromat cell antigen 1 procursor (Homo septens)
		ð	·+i	1	ĩ	6.0221	solute carrier organic anion transporter (amily, member 401 [Homo sapizne]
		<u>ن</u> ه	· faurano	4	1	0.0173	glucose transporter 1#[Horno septens]
		Q	dementer de la constante	Ť	1	NeM	serine hydroxymethylaansiense 1 (soluble) isolum 2 [Hemo septens]; serine hydroxymethylaansiense 1 (solub
		Ø		1	Ť	0.982	calcium binding protain P22 (Howo capiens)
-t-11761791 0		Ş		1	1	0.0170	[anaique amoiti] 2 gainteano alaundo ideue
		Q	*****	*	4	6.6847	CDS1 antigen [Fiomo septens]
		ý	4	*	2	0.0263	aolute carrier lamily 5 (aodium/glucose ostransporter), member 2 (Homo sapiens)
		Q		1	1	0.0728	Mir, microtubule interacting and transport, domain containing f [How sepiens]
		Q		1	8	NeN	ubiquitin protein ligase E30 [Homo sapiene]
	ģ	Q		*	1	0.0763	syntaxis 8 filonis sapilens)
		Q		+	1	0.6494	sorting asxin 3 [Horao sapiens]
		Q			14	0.0305	glueoze phosphale learnezese (Hama aspiena)
	๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛๛	Q		1	ŧ	1.6237	GDP discoclation inhibitor 2 locions 1 (Hema septens)
		Q		1	ť	NeM	solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isolores c [flored saper
*****		÷	an formation of the second	1	ţ	0.0697	RASIs, member RAS encagene family [Home septens]
	ennýn með sa sa sen se	Q	างรุ่งการการการการการการการการการการการการการก	1	1	NaN	complement component d, gamma polypeptide (Homo sapiena)
	manter and a second			1	¥	NaN	gransietoine nuorona t (ravuo sapiens); sunsietoine sotorm 2 (riono sapiens); manaketoine nuorona 1 (riom
		Q		1	1	财活税	cyclin M3 isoterm 1 (Homo septens); sydlit M3 isoterm 2 (Home septens)
		÷		1	1	经面除	solute samer tamity 9 (sodium/sydrogen exchanger), isokern a [Home sopiens]
		<u>ن</u> ه			ĩ	396034	HABSU, member HAS oncogene tamity isolorm a promo saguenas; HABSU, member HAS oncogene ramity isolor
	****	÷		1	1	0.0348	pyruvale Kinase, aver and HBC isoform t [Homo saperna]
		÷	ndrame and and a	1	2	0.0479	Linal (Espath homolog, automnity A, meeter T prome saplens]
	e	\$*****		1	1	0.0375	serine mempirator i [recito septens].
	างน้ำมากเสียการาย	÷	wijaar an de server	1	3	Ma Ni	carbonia anhydrase XII jeoform 2 precursor filomo supienej; carbonia antiydrase XII isofam 1 precursor filomo
		÷		1	3	0.0529	cathelicidin antimicrobial paptide (Homo saplaraf
		·@		1	2	8.0214	econtase 1 [Homo saplens]

Figure 3 (cont'd)

25

URINE BIOMARKERS FOR PREDICTION **OF RECOVERY AFTER ACUTE KIDNEY INJURY: PROTEOMICS**

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant #DK 070910 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation ¹⁵ of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal 20 recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

BACKGROUND

Acute Kidney Injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al. "Incidence and outcomes in acute kidney injury: a comprehensive population-based study" J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% 30 of all people admitted to intensive care units around the world develop severe AM requiring dialysis. Uchino et al., "Acute renal failure in critically ill patients: a multinational, multicenter study" JAMA 294:813-818 (2005). A recent, multi-center study found that fewer than only about 60% 35 patients surviving severe AKI recovered renal function by two months. Palevsky et al., "Intensity of renal support in critically ill patients with acute kidney injury" N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI go on to have end-stage renal disease (ESRD).

However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or providing renal support (e.g. early dialysis) cannot be targeted appropriately without some means of determining which patients will recover and which will not. 45 Unfortunately, clinical risk prediction for recovery after AKI is extremely limited. Research efforts to treat AM and prevent ESRD could be tailored according to long-termprognosis. In other words, with an accurate prediction of which patients will not recover kidney function, medical 50 efforts could focus the development and application of aggressive treatment interventions on just these patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects.

Thus, development of a biomarker or biomarker panel that allows early prediction of recovery of kidney function would be an extremely valuable clinical tool. What is needed in the art are a panel of biomarkers to predict renal recovery after AKI.

SUMMARY

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease 65 may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery

can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

In one embodiment, the present invention contemplates a composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, interalpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor. In one embodiment, the composition further comprises a urine sample. In one embodiment, the urine sample is collected between 1 day and 14 days after a kidney injury. In one embodiment, the urine sample is a human urine sample. In one embodiment, the biomarker is at least 2.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.5 fold lower 40 as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold lower as compared to an expected level in a renal recovery group.

In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a renal injury biomarker; b) measuring a renal recovery biomarker value; c) comparing said said renal biomarker value to an expected value from a renal recovery group; and d) predicting a probability of renal 55 recovery for said patient based upon said comparison. In one embodiment, the probability of renal recovery is greater than 90%. In one embodiment, the probability of renal recovery is greater than 75%. In one embodiment, the probability of renal recovery is greater than 50%. In one embodiment, the 60 probability of renal recovery is less than 50%. In one embodiment, the probability of renal recovery is less than 25%. In one embodiment, the probability of renal recovery is less than 10%. In one embodiment, the biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phos-

phoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement 5 factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor Glade A 10 member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a 15 kit, comprising; a) a first container comprising an antibody specifically directed to an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor 20 pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement com- 25 ponent precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, interalpha globulin inhibitor H4, heparan sulfate proteoglycan 2, 30 N-acylshingosine aminohydrolase, serine proteinase inhibitor Glade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor; b) 35 instructions for determining whether said biomarker is overexpressed as compared to an expected value from a renal recovery group; c) instructions for determining whether said biomarker is underexpressed as compared to an expected value from a renal recovery group; and d) instructions for 40 determining the probability of renal recovery. In one embodiment, the antibody is a monoclonal antibody. In one embodiment, the monoclonal antibody is specifically directed to said biomarker protein fragment.

In one embodiment, the present invention contemplates a 45 signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of under- 50 expressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, 55 the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic 60 recovery. anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal non-recovery. In one embodiment, the biomarker panel com- 65 prises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of

4

underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a plurality of renal biomarker nucleic acids; b) expressing said plurality of renal biomarker nucleic acids, thereby creating a signature expression profile; and c) predicting a probability of renal recovery for said patient based upon said signature expression profile. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 90%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 75%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 25%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 10%. In one embodiment, the signature expression profile comprises a plurality of overexpressed urinary proteins. In one embodiment, the signature expression profile comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising reagents for creating a signature expression profile using a biological sample, wherein said signature expression profile comprises a plurality of renal biomarker nucleic acids; b) a second container comprising monoclonal antibodies specific for said renal biomarker nucleic acids; c) a set of instructions for creating said signature expressed renal biomarker nucleic acids; e) a set of instructions for determining overexpressed renal biomarker nucleic acids; f) a set of instructions for predicting the probability of renal recovery; and g) a set of instructions for predicting the probability of renal non-recovery.

DEFINITIONS

As used herein, an "injury to renal function" is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury to renal function may be identified, for example, by a decrease in glomerular filtration rate (GFR) or estimated GFR (eGFR), a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy (i.e., ⁵ for example, dialysis), etc.

As used herein, an "improvement in renal function" is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.

As used herein, "reduced renal function" is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL (\geq 8.8 µmol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from 20 baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).

As used herein, "acute renal failure" or "ARF" is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more 25 preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl (\geq 26.4 µmol/l), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output 30 (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with "acute kidney injury" or "AKI."

As used herein, the term "relating a signal to the presence or amount" of an analyte refers to assay measurements using 35 a standard curve calculated with known concentrations of the analyte of interest. The skilled artisan will understand that the signals obtained from an assay are often a direct result of complexes formed between, for example, one or more antibodies and a target biomolecule (i.e., for example, 40 an analyte) and/or polypeptides containing an epitope(s) to which, for example, antibodies bind. While such assays may detect a full length biomarker and the assay result may be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such "immu-45 noreactive" polypeptides present in the sample.

As the term is used herein, an assay is "configured to detect" an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. For example, an 50 antibody epitope is usually on the order of 8 amino acids, such that an immunoassay can be configured to detect a marker of interest that will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or 55 antibodies used in the assay.

The term "related marker" or "biomarker" as used herein with regard to a physiological substance such as one of the proteins as described herein. A related marker may also refer to one or more fragments, variants, etc., of a particular 60 protein and/or peptide or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc. 6

The term "subject" or "patient" as used herein, refers to a human or non-human organism. Thus, the methods and compositions described herein are equally applicable to both human and veterinary disease. Further, while a subject or patient is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects or patients are humans, which as used herein refer to living humans that are receiving medical care for a disease or condition.

The term "analyte" as used herein, refers to any measured compound or molecule. Preferably, an analyte is measured in a sample (i.e., for example, a body fluid sample). Such a sample may be obtained from a subject or patient, or may be obtained from biological materials intended to be provided to the subject or patient. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, such that an analyte measurement may be used to evaluate the kidney for preexisting damage.

The term "body fluid sample" as used herein, refers to any sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing medical condition or the effect of a treatment regimen on a medical condition. Preferred body fluid samples include but are not limited to, blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, or pleural effusions. In addition, certain body fluid samples may be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.

The term "diagnosis" as used herein, refers to methods by which trained medical personnel can estimate and/or determine the probability (i.e., for example, a likelihood) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, "diagnosis" includes correlating the results of an assay (i.e., for example, an immunoassay) for a renal biomarker of the present invention, optionally together with other clinical indicia, to determine the occurrence or nonoccurrence of an acute renal injury or acute renal failure for a subject or patient from which a sample was obtained and assayed. That such a diagnosis is "determined" is not meant to imply that the diagnosis is 100% accurate. Thus, for example, a measured biomarker level below a predetermined diagnostic threshold may indicate a greater likelihood of the occurrence of a disease in the subject relative to a measured biomarker level above the predetermined diagnostic threshold may indicate a lesser likelihood of the occurrence of the same disease.

The term "prognosis" as used herein, refers to a probability (i.e., for example, a likelihood) that a specific clinical outcome will occur. For example, a level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being "indicative of an increased likelihood" of an adverse outcome in a patient.

The term "RIFLE" criteria, as used herein, refers to any quantitative clinical evaluation of renal status used to establish renal classifications of Risk, Injury, Failure, Loss, & End Stage Renal Disease based upon a uniform definition of acute kidney injury (AKI). Kellum, Crit. Care Med. 36: S141-45 (2008); and Ricci et al., Kidney Int. 73, 538-546 (2008), each hereby incorporated by reference in its entirety.

The term, "modified RIFLE criteria", as used herein, provide alternative classifications for stratifying AKI

65

patients, and may include, Stage I, Stage II, and/or Stage III. Mehta et al., Crit. Care 11:R31 (2007), hereby incorporated by reference in its entirety.

The term, "Stage I", as used herein, refers to a risk stratification comprising a RIFLE Risk category, characterized by an increase in serum creatinine of more than or equal to 0.3 mg/dL (\geq 26.4 µmol/L) and/or an increase to more than or equal to 150% (1.5-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 6 hours.

The term, "Stage II", as used herein, refers a risk stratification comprising a RIFLE Injury category, characterized by an increase in serum creatinine to more than 200% (>2-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 12 hours.

The term, "Stage III", as used herein, refers to a risk stratification comprising a RIFLE Failure category, characterized by an increase in serum creatinine to more than 300% $_{20}$ (>3-fold) from baseline and/or serum creatinine >354 µmol/L accompanied by an acute increase of at least 44 µmol/L. Alternatively, the category may be defined by a urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours. 25

The term "Risk category", as used herein, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 1.5 fold from baseline, or urine production of <0.5 ml/kg body weight/hr for approximately 6 hours.

The term "Injury category" as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 2.0 fold from baseline or urine production <0.5 ml/kg/hr for 12 h.

The term "Failure category" as used herein includes, 35 refers to a RIFLE classification wherein, in terms of serum creatinine means any increase of at least 3.0 fold from baseline or a urine creatinine $>355 \mu mol/1$ (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h, or anuria for at least 12 hours. 40

The term "Loss category" as used herein, refers to a clinical outcome risk and/or a RIFLE classification wherein the clinical outcome risk is characterized by a persistent need for renal replacement therapy for more than four weeks.

The term "End Stage Renal Disease category" or "ESRD category" as used herein, refers to a clinical outcome risk and/or a RIFLE classification characterized by a need for dialysis for more than 3 months.

The term "clinical outcome risk" as used herein, refers to 50 a medical prognosis directed towards either renal recovery or renal non-recovery.

The term "renal biomarker" as used herein, refers to any biological compound related to the progressive development of chronic kidney disease. In particular, a renal biomarker 55 may be a kidney injury marker. For example, a renal biomarker may comprise a urinary protein, or any metabolite and/or derivative thereof, wherein the renal biomarker is either overexpressed or underexpressed as a result of an AKI. 60

The term "positive going biomarker" as that term is used herein, refers to any biomarker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

The term "negative going biomarker" as that term is used herein, refer to any biomarker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

The term "positive going renal biomarker value" as used herein, refers to any increased likelihood (i.e., for example, increased probability) of suffering a future injury to renal function assigned to a subject when the measured biomarker concentration is above a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is below the specified threshold value. Alternatively, when the measured biomarker concentration is below a specified threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is above the specified threshold value. Alternatively, when the measured biomarker concentration is below the threshold value, an improvement of renal function may be assigned to the subject. A positive going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.

The term "negative going renal biomarker value" as used herein, refers to any increased likelihood (i.e., for example, an increased probability) of suffering a future injury to renal function assigned to the subject when the measured biomarker concentration is below a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is above the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an increased likelihood of a nonoccurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is below the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an improvement of renal function may be assigned to the subject. A negative going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AM, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.

The term "pre-existing" and "pre-existence" as used herein, means any risk factor (i.e., for example, a renal biomarker) existing at the time a body fluid sample is obtained from the subject.

The term "predicting" as used herein, refers to a method of forming a prognosis and/or a stratification risk assignment, wherein a medically trained person analyzes biomarker information, and optionally with relevant clinical indicia and/or demographic information.

The term "acute renal disease/failure/injury" as used herein, refers to any progressive worsening of renal function over hours to Days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances may also be referred to as, azotemia. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.

The term "chronic renal disease/failure/injury" as used herein, refers to a medical condition wherein exemplary symptoms may include, but are not limited to, hyperphosphatemia (i.e., for example, >4.6 mg/dl) or low glomerular filtration rates (i.e., for example, <90 ml/minute per 1.73 m2 of body surface). However, many CKD patients may have normal serum phosphate levels in conjunction with a sustained reduction in glomerular filtration rate for 3 or more 5 months, or a normal GFR in conjunction with sustained evidence of a structural abnormality of the kidney. In some cases, patients diagnosed with chronic kidney disease are placed on hemodialysis to maintain normal blood homeostasis (i.e., for example, urea or phosphate levels). Alterna- 10 tively, "chronic kidney disease" refers to a medical condition wherein a patients has either i) a sustained reduction in GFR <60 mi/min per 1.73 m2 of body surface for 3 or more months; or ii) a structural or functional abnormality of renal function for 3 or more months even in the absence of a 15 reduced GFR. Structural or anatomical abnormalities of the kidney could be defined as, but not limited to, persistent microalbuminuria or proteinuria or hematuria or presence of renal cysts. Chronic renal failure (chronic kidney disease) may also result from an abnormal loss of renal function over 20 months to years. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.

The term "about" as used herein in the context of any of any assay measurements refers to $\pm -5\%$ of a given mea- 25 surement.

The term "asymptomatic" as used herein, refers to a patient and/or subject that does not have a renal disease and/or injury, wherein a renal disease and/or injury symptom may include, but is not limited to, having a reduced glom- 30 erular filtration rate (i.e., for example, between approximately 70-89 ml/min per 1.73 m2 of body surface) for less than three months.

The term "glomerular filtration rate" as used herein, refers to any measurement capable of determining kidney function. 35 In general, a normal glomerular filtration rate ranges between approximately 120-90 ml/minute per 1.73 m2 of body surface. Compromised kidney function is assumed when glomerular filtration rates are less than 90 ml/minute per 1.73 m2 of body surface. Kidney failure is probable 40 when glomerular filtration rates fall below approximately 30 ml/minute per 1.73 m2 of body surface. Dialysis is frequently initiated when glomerular filtration rates fall below approximately 15 ml/minute per 1.73 m2 of body surface.

The term "renal failure" as used herein, refers to any 45 acute, sudden, and/or chronic loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes.

The term "biological sample" as used herein, refers to any substance derived from a living organism. For example, a 50 sample may be derived from blood as a urine sample, serum sample, a plasma sample, and or a whole blood sample. Alternatively, a sample may be derived from a tissue collected, for example, by a biopsy. Such a tissue sample may comprise, for example, kidney tissue, vascular tissue and/or 55 heart tissue. A biological sample may also comprise body fluids including, but not limited to, urine, saliva, or perspiration.

The term "reagent" as used herein, refers to any substance employed to produce a chemical reaction so as to detect, 60 measure, produce, etc., other substances. The term "antibody" as used herein refers to any peptide or polypeptide derived from, modeled after, or substantially encoded by, an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or 65 epitope. See, e.g. In: Fundamental Immunology, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson et al., J.

Immunol. Methods 175:267-273 (1994); and Yarmush et al., J. Biochem. Biophys. Methods 25:85-97 (1992). The term antibody includes, but is not limited to, antigen-binding portions, i.e., "antigen binding sites" exemplified by fragments, subsequences, and/or complementarity determining regions (CDRs)) that retain capacity to bind antigen, including, but not limited to: (i) a Fab fragment, a monovalent fragment comprising VL, VH, CL or CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment comprising VH and CH1 domains; (iv) a Fv fragment comprising VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341:544-546 (1989)), which comprises a VH domain; or (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term "antibody."

The term "epitope" as used herein, refers to any antigenic determinant capable of specific binding to an antibody. Epitopes usually display chemically active surface molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes may be distinguished in that the binding to the former but not the latter can be lost in the presence of denaturing solvents.

The term "correlating" as used herein, in reference to the use of biomarkers, refers to comparing the presence and/or amount of any biomarker(s) in a patient to its presence and/or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 presents exemplary subject information relevant to the Biological Markers of Recovery for the Kidney (Bio-MaRK) study cohort used as the basis for some of the data analysis presented herein.

FIG. **2**: Representative protein biomarker families identified by a proteomics platform

FIG. **3** Representative single biomarker peptides Identified by a proteomics platform.

DETAILED DESCRIPTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

Despite significant advances in the epidemiology of acute kidney injury (AKI), prognostication remains a major clinical challenge. Unfortunately, there is no reliable method to predict renal recovery. The discovery of biomarkers to aid in clinical risk prediction for recovery after AM would represent a significant advance over current practice. I. Kidney Injury and/or Disease

The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acidbase balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As 5 such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by 10 reference in their entirety. The kidneys are located in the flank (back of the upper abdomen at either side of the spinal column) They are deep within the abdomen and are protected by the spine, lower rib cage, and the strong muscles of the back. This location protects the kidneys from many 15 external forces. They are well-padded for a reason-kidneys are highly vascular organs, which means that they have a large blood supply. If injury occurs, severe bleeding may result

Kidneys may be injured by damage to the blood vessels ²⁰ that supply or drain them. This may be in the form of aneurysm, arteriovenous fistula, arterial blockage, or renal vein thrombosis. The extent of bleeding depends on the location and the degree of injury. Kidneys may also bleed profusely if they are damaged centrally (on the inside)—this ²⁵ is a life-threatening injury. Fortunately, most kidney injuries caused by blunt trauma occur peripherally, only causing bruising of the kidney (usually a self-limiting process).

People with undiagnosed kidney conditions—such as angiomyolipoma (benign tumor), ureteropelvic junction 30 obstruction (congenital or acquired UPJ Obstruction), and other disorders—are more susceptible to kidney injuries and more likely to have serious complications if they occur. Other causes of kidney injury and bleeding are medical procedures. Kidney biopsies, nephrostomy tube placements, or other surgeries can cause an abnormal connection between an artery and vein (arteriovenous fistula). This is usually a self-limiting problem, but close observation is usually needed. Injury to the kidney can also disrupt the urinary tract, causing leakage of the urine from the kidney.

Each kidney filters about 1700 liters of blood per Day and ⁴⁰ concentrates fluid and waste products into about 1 liter of urine per Day. Because of this, the kidneys receive more exposure to toxic substances in the body than almost any other organ. Therefore, they are highly susceptible to injury from toxic substances. Analgesic nephropathy is one of the ⁴⁵ most common types of toxic damage to the kidney. Exposure to lead, cleaning products, solvents, fuels, or other nephrotoxic chemicals (those which can be toxic to the kidney) can damage kidneys. Excessive buildup of body waste products, such as uric acid (that can occur with gout or with treatment ⁵⁰ of bone marrow, lymph node, or other disorders) can also damage the kidneys.

Inflammation (irritation with swelling and presence of extra immune cells) caused by immune responses to medications, infection, or other disorders may also injure the structures of the kidney, usually causing various types of glomerulonephritis or acute tubular necrosis (tissue death). Autoimmune disorders may also damage the kidneys. Injury to the kidney may result in short-term damage with minimal or no symptoms. Alternately, it can be life-threatening because of bleeding and associated shock, or it may result in acute renal failure or chronic renal failure.

Ureteral injuries (injuries to the tubes which carry urine from the kidneys to the bladder) can also be caused by trauma (blunt or penetrating), complications from medical procedures, and other diseases in the retroperitoneum such as retroperitoneal fibrosis (RPF), retroperitoneal sarcomas, or metastatic lymph node positive cancers. Medical thera-

pies (such as OB/GYN surgeries, prior radiation or chemotherapy, and previous abdominopelvic surgeries) increase the risk for ureteral injuries.

A. Acute Kidney Failure

Acute (sudden) kidney failure is the sudden loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes. There are many possible causes of kidney damage including, but are not limited to, decreased blood flow, which may occur with extremely low blood pressure caused by trauma, surgery, serious illnesses, septic shock, hemorrhage, burns, or dehydration, acute tubular necrosis (ATN), infections that directly injury the kidney such as acute pyelonephritis or septicemia, urinary tract obstruction (obstructive uropathy), autoimmune kidney disease such as interstitial nephritis or acute nephritic syndrome, disorders that cause clotting within the thin blood vessels of the kidney, idiopathic thrombocytopenic thrombotic purpura (ITTP), transfusion reaction, malignant hypertension, scleroderma, hemolytic-uremic syndrome, disorders of childbirth, such as bleeding placenta abruptio or placenta previa

Symptoms of acute kidney failure may include, but are not limited to, decrease in amount of urine (oliguria), urination stops (anuria), excessive urination at night, ankle, feet, and leg swelling, generalized swelling, fluid retention, decreased sensation, especially in the hands or feet, decreased appetite, metallic taste in mouth, persistent hiccups, changes in mental status or mood, agitation, drowsiness, lethargy, delirium or confusion, coma, mood changes, trouble paying attention, hallucinations, slow, sluggish, movements, seizures, hand tremor (shaking), nausea or vomiting, may last for Days, bruising easily, prolonged bleeding, nosebleeds, bloody stools, flank pain (between the ribs and hips), fatigue, breath odor, or high blood pressure.

Acute renal failure (ARF) may also be referred to as acute kidney injury (AKI) and may be characterized by an abrupt (i.e., for example, typically detected within about 48 hours to 1 week) reduction in glomerular filtration rate (GFR). This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in association with their respective risk factors are summarized below. See, Table 4; In: Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety.

TABLE 4

55	Rep	resentative Acute Renal Failure Risk Factors
	Type of Renal Failure	Risk Factors
	Prerenal	_
60	ECF volume depletion	Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states
65	Low cardiac	Cardiomyopathy, MI, cardiac tamponade, pulmonary

mechanical ventilation

TABLE 4-continued

Representative Acute Renal Failure Risk Factors									
Type of Renal Failure	Risk Factors								
Low systemic vascular resistance Increased renal vascular resistance Decreased efferent arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis) Intrinsic Renal	Septic shock, liver failure, antihypertensive drugs NSAIDs, cyclosporines, tacrolimus, hypercalcemia, anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome ACE inhibitors or angiotensin II receptor blockers								
Acute tubular injury Acute glomerulo- nephritis Acute tubulointerstitial nephritis Acute vascular nephropathy Infiltrative diseases Postrenal	Ischemia (prolonged or severe prerenal state): surgery, hemorrhage, arterial or venous obstruction; Toxins: NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin ANCA-associated: Crescentic glomerulonephritis, polyarteritis nodosa, Wegener's granulomatosis; Anti- GBM glomerulonephritis: Goodpasture's syndrome; Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis Drug reaction (eg, β -lactams, NSAIDs, sulfonamides, ciprofloxacin, thiazide diuretics, furosemide, phenytoin, allopurinol, pyelonephritis, papillary necrosis Vasculitis, malignant hypertension, thrombotic microangiopathies, scleroderma, atheroembolism Lymphoma, sarcoidosis, leukemia								
Tubular precipitation Ureteral obstruction Bladder obstruction	Uric acid (tumor lysis), sulfonamides, triamterene, acyclovir, indinavir, methotrexate, ethylene glycol ingestion, myeloma protein, myoglobin Intrinsic: Calculi, clots, sloughed renal tissue, fungus ball, edema, malignancy, congenital defects; Extrinsic: Malignancy, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury Mechanical: Benign prostatic hyperplasia, prostate cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter; Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion								

In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, 55 which lasts hours to Days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and 65 glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is

repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.

Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of Days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to 10 be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 Days, resolution within 1 week) rise 15 in blood urea nitrogen and serum creatinine.

A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 Days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and 20 detect AM is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AM varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 25 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI.

For example, relationships between elevated serum creatinine and AKI has been reported to be associated with 30 health risks. Fraught et al., Curr Opin Nephrol Hypertens 14:265-270 (2005); and Chertow et al., J Am Soc Nephrol 16:3365-3370 (2005) (both references are herein incorporated by reference in their entirety). As described in these publications, acute worsening renal function (AKI) and 35 increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These creatinine increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from 4∩ the pre-injury value have been reported to indicate acutely worsening renal function (AM) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 45 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 Days, 3 Days, 7 Days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.

Another study correlated serum creatinine levels with post-surgical mortality rates. Following heart surgery, patients with a mild fall in serum creatinine (i.e., for example, between approximately -0.1 to -0.3 mg/dL) had the lowest mortality rate, wherein patients had a larger mortality rate associated with either large falls in serum creatinine (i.e., for example, more than or equal to -0.4mg/dL), or an increase in serum creatinine. Lassnigg et al., JAm Soc Nephrol 15:1597-1605 (2004), herein incorporated by reference in its entirety. These findings suggested that even very subtle changes in renal function, as detected by small creatinine changes within 48 hours of surgery, can be predictive of a patient's outcome.

A unified classification system using serum creatinine to define AM in clinical trials and in clinical practice was proposed to stratify AKI patients. Bellomo et al., *Crit Care* 8(4):R204-212 (2004), which is herein incorporated by reference in its entirety. For example, a serum creatinine rise 5 of 25% may define contrast-induced nephropathy. McCollough et al, *Rev Cardiovasc Med.* 7(4):177-197 (2006), herein incorporated by reference in its entirety. Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small 10 changes in serum creatinine, such as 0.3 mg/dL (i.e., for example, approximately 25%) are sufficient to detect AM that characterizes a worsening renal function and that the magnitude of the serum creatinine change may be an indicator of the severity of the AKI and mortality risk. 15

Although serial measurement of serum creatinine over a period of Days is an accepted method of detecting and diagnosing AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for 20 serum creatinine to rise to approximately 0.3 mg/dL (25%) is considered diagnostic for AM can be 48 hours or longer depending on the definition used.

Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or 25 longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Until defined 30 by some embodiments of the present invention, there were no methods to determine whether some patients with AKI would recover fully, or whether some would need dialysis (either short term or long term), or whether some would have other detrimental outcomes including, but not limited 35 to, death, major adverse cardiac events or chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic 40 renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited.

These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and 45 repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.

B. Chronic Kidney Failure

Unlike acute renal failure, chronic renal failure slowly gets worse. It most often results from any disease that causes 50 gradual loss of kidney function. It can range from mild dysfunction to severe kidney failure. Chronic renal failure may lead to end-stage renal disease (ESRD).

Chronic renal failure usually occurs over a number of years as the internal structures of the kidney are slowly 55 damaged. In the early stages, there may be no symptoms. In fact, progression may be so slow that symptoms do not occur until kidney function is less than one-tenth of normal.

Chronic renal failure and ESRD affect more than 2 out of 1,000 people in the United States. Diabetes and high blood 60 pressure are the two most common causes and account for most cases. Other major causes include, but are not limited to, Alport syndrome, analgesic nephropathy, glomerulone-phritis of any type (one of the most common causes), kidney stones and infection, obstructive uropathy, polycystic kidney 65 disease, or reflux nephropathy. Chronic renal failure results in an accumulation of fluid and waste products in the body,

leading to a build up of nitrogen waste products in the blood (azotemia) and general ill health. Most body systems are affected by chronic renal failure.

Initial symptoms may include, but are not limited to, fatigue, frequent hiccups, general ill feeling, generalized itching (pruritus), headache, nausea, vomiting, or unintentional weight loss. Further, later symptoms may include, but are not limited to, blood in the vomit or in stools,

decreased alertness, including drowsiness, confusion, delirium, orcoma, decreased sensation in the hands, feet, or other areas, easy bruising or bleeding, increased or decreased urine output, muscle twitching or cramps, seizures, or white crystals in and on the skin (uremic frost).

Circulating levels of cytokines and other inflammation 15 markers are markedly elevated in patients with chronic renal failure. This could be caused by increased generation, decreased removal, or both. However, it is not well established to what extent renal function per se contributes to the uremic proinflammatory milieu. Relationships between inflammation and glomerular filtration rate (GFR) were reported in 176 patients (age, 52+/-1 years; GFR, 6.5+/-0.1 mL/min) close to the initiation of renal replacement therapy. Pecoits-Filho et al., "Associations between circulating inflammatory markers and residual renal function in CRF patients" Am J Kidney Dis. 41(6):1212-1218 (2003). For example, circulating levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), hyaluronan, and neopterin were measured after an overnight fast. Patients subsequently were subdivided into two groups according to median GFR (6.5 mL/min). Despite the narrow range of GFR (1.8 to 16.5 mL/min), hsCRP, hyaluronan, and neopterin levels were significantly greater in the subgroup with lower GFRs, and significant negative correlations were noted between GFR and IL-6 (rho=-0.18; P<0.05), hyaluronan (rho=-0.25; P<0.001), and neopterin (rho=-0.32; P<0.0005). In a multivariate analysis, age and GFR were associated with inflammation but cardiovascular disease and diabetes mellitus were not. These results show that a low GFR per se is associated with an inflammatory state, suggesting impaired renal elimination of proinflammatory cytokines, increased generation of cytokines in uremia, or an adverse effect of inflammation on renal function.

C. Dialysis

Dialysis (i.e., for example, renal replacement therapy) is a method of removing toxic substances (impurities or wastes) from the blood when the kidneys are unable to do so and can be performed using several different methods. For example, peritoneal dialysis may filter waste by using the peritoneal membrane inside the abdomen. The abdomen is filled with special solutions that help remove toxins. The solutions remain in the abdomen for a time and then are drained out. This form of dialysis can be performed at home, but must be done every Day. Alternatively, hemodialysis may be performed by circulating the blood through special filters outside the body. The blood flows across a filter, along with solutions that help remove toxins.

Dialysis uses special ways of accessing the blood in the blood vessels. The access can be temporary or permanent. Temporary access takes the form of dialysis catheters hollow tubes placed in large veins that can support acceptable blood flows. Most catheters are used in emergency situations for short periods of time. However, catheters called tunneled catheters can be used for prolonged periods of time, often weeks to months. Permanent access is created by surgically joining an artery to a vein. This allows the vein to receive blood at high pressure, leading to a thickening of the vein's wall. This vein can handle repeated puncture and also provides excellent blood flow rates. The connection between an artery and a vein can be made using blood vessels (an arteriovenous fistula, or AVF) or a synthetic bridge (arteriovenous graft, or AVG). Blood is diverted from 5 the access point in the body to a dialysis machine. Here, the blood flows counter-current to a special solution called the dialysate. The chemical imbalances and impurities of the blood are corrected and the blood is then returned to the body. Typically, most patients undergo hemodialysis for 10 three sessions every week. Each session lasts 3-4 hours. The purpose of dialysis is to assist kidney functions including, filters for the blood, removing waste products, regulating body water, maintaining electrolyte balance, or maintaining blood pH remains between 7.35 and 7.45. Further, 15 dialysis may replace some of the functions for kidneys that aren't working properly that would otherwise result in the death of a patient.

Dialysis is most often used for patients who have kidney failure, but it can also quickly remove drugs or poisons in 20 acute situations. This technique can be life saving in people with acute or chronic kidney failure.

II. Urinary Renal Biomarkers

Currently, no effective treatments exist to improve renal recovery, or to improve short and long-term renal outcome, 25 after AKI. Furthermore, methods to predict recovery are also lacking. The emerging role of biomarkers for early detection of renal disease and/or renal injury may help identify new prognostic tools to predict renal clinical outcomes. Potential candidates for biomarkers of renal recovery include, but are 30 not limited to, molecules expressed in pathways leading to regeneration and proliferation as well as markers of fibrosis and apoptosis. In addition, renal injury biomarkers may also serve to distinguish early resolution, and hence increased odds of recovery. 35

Acute kidney injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al., "Incidence and outcomes in acute kidney injury: a comprehensive population-based study" J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% 40 of all people admitted to intensive care units around the world develop severe AM requiring dialysis. Uchino et al., "Acute renal failure in critically ill patients: a multinational, multicenter study" JAMA 294:813-818 (2005). A recent, United States multi-center study found that fewer than only 45 about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., "Intensity of renal support in critically ill patients with acute kidney injury" N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI progress into end-stage renal disease 50 (ESRD)

However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or at providing renal support (e.g. early dialysis) cannot be selectively targeted appropriately without some 55 means of determining which patients will recover and which will not recover (i.e., for example, the availability of noninvasive biomarkers). Currently, clinical risk prediction for recovery after AKI is extremely limited. Thus, development of a non-invasive biomarker that allows early prediction of 60 recovery of kidney function is a long felt need in the art of renal disease management.

The identification of such non-invasive biomarkers (i.e., for example, a urinary biomarker) would greatly improve long-term prognosis thereby tailoring research efforts to 65 treat AM and prevent ESRD. In other words, having the ability to predict which patients will not recover kidney

function allows a clinician to focus limited resources on the development and application of aggressive treatment interventions on these predicted at-risk patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects, thereby releasing medical resources to those in need and reducing overall medical costs.

In one embodiment, the present invention contemplates methods and compositions for evaluating renal function in a subject. As described herein, measurement of various kidney injury markers described herein can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and a determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).

Renal biomarkers as described herein may be used individually, or in panels, comprising a plurality of renal biomarkers, for risk stratification. In one embodiment, risk stratification identifies subjects at risk for a future: i) injury to renal function; ii) progression to reduced renal function; iii) progression to ARF; or iv) improvement in renal function, etc. In one embodiment, risk stratification diagnoses an existing disease, comprising identifying subjects who have: i) suffered an injury to renal function; ii) progressed to reduced renal function; or iii) progressed to ARF, etc. In one embodiment, risk stratification monitors for deterioration and/or improvement of renal function. In one embodiment, risk stratification predicts a future medical outcome including, but not limited to, an improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require initiation or continuation of renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc.

III. Clinical Renal Biomarker Studies

The results of a large multicenter clinical trial has recently been reported comparing two intensities of renal support for critically ill patients with acute kidney injury (AKI) in which recovery of renal function was less than 25% at 28 days and not different between the two treatment strategies. Palevsky et al., "Intensity of renal support in critically ill patients with acute kidney injury" N Engl J Med 359:7-20 (2008). These results emphasize that incomplete renal recovery is a common problem in the patients who survive severe AKI. Uchino et al., "Acute renal failure in critically ill patients: a multinational, multicenter study" JAMA, 294: 813-818 (2005). Failure to recover renal function can have tremendous negative effects on quality of life and health care costs. Manns et al., "Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery" Crit Care Med, 31:449-455 (2003). Therefore, treatments to hasten and facilitate renal recovery are eagerly being sought by both the critical care and nephrology communities. Unfortunately, there are no effective treatments to improve renal recovery. One possible barrier to progress in this area has been the inability to forecast recovery in individual patients. The ability to prognosticate in an AKI patient population would be extremely

valuable both for clinical decisions as well as to guide future research on therapy to promote recovery of renal function.

One clinical study reported that patients who recovered from AKI did not appear to differ in clinical characteristics (i.e., for example, age, gender, mechanical ventilation status, or clinical severity scores) from the non-recovery group. Bhandari et al., "Survivors of acute renal failure who do not recover renal function" QJM, 89:415-421 (1996). Secondary analysis from three randomized controlled trials (RCTs) comparing efficacy of continuous renal replacement therapy (RRT) versus intermittent RRT found that: i) APACHE III scores >100; ii) cardiovascular instability; and iii) preexisting renal impairment were all associated with renal non-recovery. Mehta et al., "A randomized clinical trial of 15 continuous versus intermittent dialysis for acute renal failure" Kidney Int, 60:1154-1163 (2001); Augustine et al., "A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF" Am J Kidnev Dis. 44:1000-1007 (2004); and Uehlinger et al., "Comparison of 20 continuous and intermittent renal replacement therapy for acute renal failure" Nephrol Dial Transplant, 20:1630-1637 (2005), respectively. However, these studies did not adhere to a uniform definition of, or standard timing, to assess renal recovery.

Other studies have suggested that baseline creatinine and ²⁵ urine output at the time of discontinuation of RRT were most predictive of recovery. Uchino et al., "Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study" *Crit Care Med*, 37:2576-2582 (2009). However, urine output was analyzed after RRT had ended based on a clinical decision rather than at a fixed time point (e.g. 14 Days post AKI) to predict renal recovery. Therefore, these data are compromised to suggest that urine output was predictive of renal recovery, and further, baseline creatinine might have been less valuable because patients with stage 4 and 5 CKD were excluded.

Recently, a number of urinary biomarkers have been investigated for the purpose of early diagnosis of AM. Since these markers correlate with renal tubular cell injury or function, their patterns in the urine, either alone or in combination, could provide new prognostic information regarding renal recovery. For example, several reports have suggested possible candidate renal biomarkers relating to three aspects of the physiology of renal recovery: 45

i) inflammatory markers including; a) urinary neutrophil gelatinase-associated lipocalin (uNGAL), which has been extensively studied for predicting AKI (Supavekin et al., "Differential gene expression following early renal ischemia/reperfusion" *Kidney Int*, 63:1714-1724 (2003); Mishra et al., "Kidney NGAL is a novel early marker of acute injury

following transplantation" Pediatr Nephrol, 21:856-863 (2006); Hirsch et al., "NGAL is an early predictive biomarker of contrast-induced nephropathy in children" Pediatr Nephrol, 22: 2089-2095 (2007); and Zappitelli et al., "Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study" Crit Care, 11: R84 (2007); b) matrix metalloproteinase protein-9 (MMP-9), a matrix degradation enzyme which is up-regulated after ischemic injury in animal models and links to NGAL by a disulfide bond forming urinary NGAL/MMP-9 (uNGAL/MMP-9) (Ronco et al., "Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin" Semin Nephrol, 27:352-362 (2007); and c) urinary interleukin-18 (uIL-18), an inflammatory cytokine which is found to potentiate ischemic AKI and has been tested in many clinical settings (Parikh et al., "Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit" J Am Soc Nephrol, 16:3046-3052 (2005); and Parikh et al., "Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery" Kidney Int, 70:199-203 (2006);

ii) growth factors including urinary hepatocyte growth factor (uHGF), a biomarker linked to renal tubular epithelial cell regeneration (Liu et al., "Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? *Kidney Int*, 70:238-240 (2006); and

iii) filtration and tubular reabsorption markers, such as cystatin C, which is freely filtered and is normally completely reabsorbed by proximal tubular epithelial cells and urine creatinine. Herget-Rosenthal et al., "Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range" *Ann Clin Biochem*, 41:111-118 (2004).

Despite these reports, only a few suggest biomarkers having an ability to predict AKI severity. But no study has identified a biomarker as a predictor of renal recovery. Coca et al., "Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review" *Kidney Int*, 73:1008-1016 (2008). The data presented herein provide heretofore unknown renal biomarkers identified by proteomic gene expression analysis. The data was obtained from urine samples collected during a clinical study as described below.

The data presented herein was collected from 109 patients in the BioMaRK clinical study where 76 patients had complete data available including urine samples. Exactly half (38 patients) recovered renal function (alive and without requirement for dialysis) by day 60. See, FIG. 1. Baseline clinical characteristics of the study patients were taken. See, Table 1.

TABLE 1

Summary of baseline and clinical char	racteristics of th	e study patie	ents	
Characteristics	All subjects (n = 76)	Recovery (n = 38)	Non-recovery (n = 38)	P value
Age, mean (SD), -yr	58.4(17.0)	52.2(15.7)	64.7(16.2)	< 0.001
Gender: Female (%)	30(39.5)	15(39.5)	15(39.5)	1.00
Race: White (%)	64(84.2)	30(79.0)	34(89.5)	0.21
Baseline serum creatinine, mean (SD) (mg/dl)	1.1(0.4)	1.1(0.4)	1.2(0.5)	0.45
BUN at initiation of RRT, mean (SD) (mg/dl)	55.6(29.9)	51.3(28.8)	59.9(30.8)	0.23
Cause of acute kidney injury	_	. ,	. ,	
Ischemia (%)	66(86.8)	29(76.3)	37(97.4)	0.007
Nephrotoxins (%)	16(21.3)	10(26.3)	6(16.2)	0.29
Sepsis (%)	50(65.8)	23(60.5)	27(71.1)	0.33

TABLE 1-continued

Summary of baseline and clinical characteristics of the study patients							
Characteristics	All subjects (n = 76)	Recovery (n = 38)	Non-recovery (n = 38)	P value			
Multifactorial causes (%)	51(68.0)	25(65.8)	26(70.3)	0.68			
Length of ICU stay before randomization-days, mean (SD)	5.4(4.1)	4.2(2.8)	6.5(4.9)	0.03			
Length of hospital stay before randomization-days, mean (SD)	8.5(7.1)	6.7(5.0)	10.2(8.5)	0.08			
Charlson comorbidity index ^a , mean (SD)	4.1(3.3)	3.3(3.8)	4.9(2.7)	0.008			
Mechanical ventilation (%)	69(90.8)	34(89.5)	35(92.1)	1.00			
Sepsis ^b (%)	47(62.7)	22(57.9)	25(67.6)	0.39			
APACHE II score ^c , mean (SD)	23.4(7.2)	21.8(7.2)	25.0(6.8)	0.06			
Non-renal SOFA organ-system score ^d , mean (SD)							
Respiratory	2.1(1.3)	2.1(1.5)	2.1(1.2)	0.98			
Coagulation	1.5(1.3)	1.4(1.3)	1.5(1.3)	0.58			
Liver	0.9(1.3)	1.2(1.5)	0.6(1.0)	0.08			
Cardiovascular	2.2(1.7)	2.0(1.7)	2.5(1.6)	0.17			
Central nervous system	2.2(1.4)	2.3(1.3)	2.1(1.5)	0.45			
Total	8.9(4.0)	9.2(4.6)	8.5(3.3)	0.43			
Cleveland Clinic ICU ARF Renal Failure score ^e , mean (SD)	11.9(3.0)	11.6(3.0)	12.2(3.0)	0.49			
Intensive strategy ^f (%)	34(44.7)	18(47.4)	16(42.1)	0.64			

Abbreviations: RRT, Renal Replacement Therapy. ICU, Intensive Care Unit. APACHE II, Acute Physiology and Chronic Health Evaluation II. SOFA, Sequential Organ Failure Assessment. ARF, Acute Renal Failure. "According to the method of Charlson et al.²⁶

^bDefined as sepsis plus acute organ dysfunction according to 2001 international consensus critetia for sever sepsis.²⁶ ^cAccording to the method of Knaus et al.²⁹

^dNon renal SOFA score, excluding the renal part, assessed on the first day according to the method of Vincent et al.³⁰ eAccording to the method of Thakar et al.31

 $f_{\rm intensive strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided six times per week (every day except Sunday), and continuous venovenous hemodiafiltration was prescribed to provide a flow rate of the total effluent (the sum of the dialysate and ultrafiltrate) of 35 ml per kilogram of body weight per hour, based on the weight before the onset of acute illness.¹$

be younger, had a shorter length of intensive care unit (ICU) stay before randomization, lower Charlson comorbidity index, and lower nonrenal SOFA score as compared to those not recovering renal function. By contrast, there were no statistical differences in gender, ethnicity, baseline serum 35 summary and a per-protein biomarker detailed analysis. creatinine, blood urea nitrogen (BUN) at initiation of RRT, length of hospital stay, length of ICU stay, requirement for mechanical ventilation, Cleveland Clinic ICU Acute Renal Failure (ARF) score, or intensity of RRT. The primary etiology of AKI was ischemia in both groups. However, a 40 significantly lower percentage of ischemia (76.3%) was noted as the cause of AKI in the recovery group compared to 97.4% in non-recovery group. Of the 38 participants who recovered renal function, 26 (68.4%) had complete recovery. Among those failing to recover renal function, 25 patients 45 (65.8%), did not survive past day 60.

IV. Proteomics Gene Expression Platforms

In one embodiment, the present invention contemplates a method for identifying urinary biomarkers using a proteomics platform. In one embodiment, the proteomics platform 50 detects protein expression profiles. In one embodiment, the method further comprises comparing a first protein expression profile to a second protein expression profile. In one embodiment, the comparing identifies an overexpressed protein in the first protein expression profile relative to the 55 second protein expression profile. In one embodiment, the comparing identifies an underexpressed protein in the first protein expression profile relative to the second protein expression profile.

A Introduction

60

In one embodiment, the present invention contemplates a method comprising a proteomics platform (i.e., for example, iTRAQ) capable of summarizing an analysis of relative 65 protein biomarker expression. For example, the proteomics platform may use reporter ion peak area measurements (i.e.,

Patients recovering from renal injury were more likely to 30 for example, supplied by ABI software) to estimate treatment-dependent peptide and protein biomarker relative expression. Such estimations may be accomplished using a Bayesian approach. The proteomics platform described herein includes a protein biomarker relative expression

B Experiment and Model Description

1. Experiment Design

Proteomic platforms contemplated herein may summarize data from one or more experiments addressing a common comparison. For example, a possible experimental design for such an analysis is presented below. See, Table 5.

TABLE 5

Representative Proteomic Experimental Designs						
	Experiment	Treatment	Channel	Sample		
1	А	А	113	A1		
2	А	А	114	A2		
3	А	Α	115	A3		
4	А	А	116	A4		
5	А	В	117	B1		
6	А	В	118	B2		
7	А	В	119	B4		
8	А	В	121	B4		

2. Input Files

Data for proteomic analyses may be extracted from input files including but not limited to a tandem mass spectra (MSMS) summary file, such as:

60

Experiment MSMS Summary File A SCW_XIII_70.bit

3. Statistical Modeling

Statistical models to estimate the treatment-dependent effects may including but not limited to: LogIntensity~Chan-10 nel+Spectrum+Protein+Peptide+Protein:Treatment+Peptide: Treatment.

4. Data Summarization

The proteomics platform may comprise filtering the data supplied in the MSMS summary to remove unidentified proteins, contaminants, and/or peptides containing selected modifications. A representative analysis may provide a data summary as presented below. See, Table 6.

TABLE 6

	А	Combined	
Supplied Spectra	4608	4608	
Unidentified Spectra	0	0	
Disallowed Modifications	249	249	
Spectra from Contaminants	1210	1210	
Missing Data	115	115	
Low Confidence Spectra	0	0	
Degenerate Peptides	379	379	
Remaining Spectra		2655	
Unique Proteins		360	
Unique Peptides		1473	
~ ^			

C. Protein Biomarker Summary

In one embodiment, the proteomics platform may identify $_{40}$ each protein biomarker in one or more of the MSMS summaries, for example, in decreasing order of expression change magnitude. See, FIG. 2. The median and estimated credible interval for each protein biomarker is given to the left in the table. Similar data is shown where protein 45 biomarkers are identified by a single peptide. See FIG. 3.

D. Protein Biomarker Details

A detailed summary of each protein biomarker is given $_{50}$ below, wherein each protein biomarker is designated as 5.###. These sections include protein biomarker relative expression estimates in addition to protein-level estimates.

Lengthy table referenced here

US09551720-20170124-T00001

Please refer to the end of the specification for access instructions.

III. Renal Status Assay Measurements

The ability of a particular renal biomarker assay measurement to distinguish between two populations can be established using ROC analysis. For example, ROC curves established from a "first" subpopulation (i.e., for example, a 65 population predisposed to one or more future changes in renal status) and a "second" subpopulation (i.e., for

example, a population not predisposed to one or more future changes in renal status). Calculation of these ROC curves and establishing the area under these ROC curves quantitate the predictive power of the specific assay measurement. In some embodiments, predictive power established by assay measurements described herein comprise an AUC ROC greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.

A. Immunoassays

In general, immunoassays involve contacting a sample containing, or suspected of containing, a biomarker of interest with at least one antibody that specifically binds to the biomarker. A detectable signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The detectable signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices have been reported regarding the detection and 20 analysis of biological biomarkers. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and The Immunoassay Handbook, David Wild, ed. Stockton Press, New York, 1994, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims.

Numerous immunoassay devices and methods can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is o related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein "blotting" methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to 5 determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims. Robotic instrumentation for performing these immunoassays are commercially available including, but not limited to, Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.

Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in immunoassays. Solid phases that may be used to immobilize specific binding members include, but are not limited to those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include, but are not limited to, membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, Tenta-55 Gels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. For example, an assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.

In certain embodiments, a urinary renal biomarker assay method comprises an immunoassay. For example, antibodies for use in such assays may specifically bind an epitope of a renal biomarker of interest, and may also bind one or more polypeptides that are "related" thereto, as that term is defined hereinafter. In one embodiment, the renal biomarker of interest is a fully length marker (i.e., for example, a protein). In one embodiment, the renal biomarker of interest is a protein fragment marker (i.e., for example, a peptide). Numerous immunoassay formats are available compatible with body fluid samples including, but not limited to, urine, blood, serum, saliva, tears, and plasma.

In this regard, detectable signals obtained from an immunoassay may be a direct result of complexes formed between 15 one or more antibodies and the target biomolecule (i.e., for example, an analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of 20 interest, the signal from the assay may actually be a result of all such "immunoreactive" polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (i.e., for example, dot blots, western blots, chro- 25 matographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.

The foregoing method steps should not be interpreted to mean that the renal biomarker assay measurements is/are 30 used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, risk stratification, diagnostic, classification, monitoring, etc. methods as described herein may be combined with one or more 35 clinical indicia relevant to the patient population including, but not limited to, demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, 40 hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or 45 streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, 50 a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma 55 BUN to creatnine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concen- 60 tration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more renal biomarker assay measurements are described hereinafter. In: Harrison's 65 Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830; and In: Current Medical

Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are herein incorporated by reference in their entirety.

When more than one biomarker is measured, the individual biomarkers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual biomarkers may also be measured on the same or different body fluid samples. For example, one renal biomarker may be measured in a serum or plasma sample and another renal biomarker may be measured in a urine sample. In addition, assignment of a likelihood may combine a renal biomarker assay measurement with temporal changes in one or more additional variables.

B. Detectable Labels

Generation of a detectable signal from the detectable label can be performed using various optical, acoustical, and electrochemical methods. Examples of detection modes include, but are not limited to, fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody may be coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibodybased biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.

Biological assays require methods for detection, and one of the most common methods for quantitation of assay measurements is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels used in the immunoassays described above may include, but are not limited to, molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ec1 (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).

Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents may involve at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups and are believed to react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.

D. Assay Correlations

In some embodiments, the renal biomarker assay measurement is/are correlated to one or more future changes in renal function. In one embodiment, risk stratification comprises determining a subject's likelihood (i.e., for example, 5 probability) for a future improvement in renal function.

In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such a future improvement in renal function. In one embodiment, the method correlates a likelihood of such a future injury to 10 renal function. In one embodiment, the risk stratification comprises determining a subject's risk for progression to acute renal failure (ARF).

In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such progression to 15 acute renal failure (ARF). In one embodiment, the risk stratification method comprises determining a subject's outcome risk.

In one embodiment, the assay measurement is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject.

Consequently, the measured concentration value(s) may each be compared to a threshold value, wherein either a "positive going kidney injury marker", or a "negative going kidney injury marker" is identified. In one embodiment, the risk stratification comprises determining a subject's risk for ²⁵ future reduced renal function. In some embodiments, the method assigns a likelihood, risk, or probability that such that an event of interest is more or less likely to occur within 180 Days of the time at which the body fluid sample is obtained from the subject. In some embodiments, the 30 assigned likelihood, risk, or probability relates to an event of interest occurring within a time period including, but not limited to, 18 months, 120 Days, 90 Days, 60 Days, 45 Days, 30 Days, 21 Days, 14 Days, 7 Days, 5 Days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. 35 Alternatively, assigning a risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.

Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribu-40 tion of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncer- 45 tainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, a cost/ benefit analysis is involved in selecting a diagnostic threshold. 50

1. Thresholds

Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction uses cardiac troponin, wherein the diagnostic threshold is set at the 97.5th percentile of the cardiac troponin concentration measured in a normal population. Another method to determine a diagnostic threshold comprises measuring serial samples from the same patient, where a prior "baseline" result is used to monitor for temporal changes in a biomarker level.

Population studies may also be used to select thresholds. ⁶⁰ For example, Receiver Operating Characteristic ("ROC") arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold to distinguish a "diseased" subpopulation from a "nondiseased" 65 subpopulation. Predictive power balances the occurrences of false positives (i.e., for example, when the person tests

positive, but actually does not have the disease) and false negatives (i.e., for example, when the person tests negative, suggesting they are healthy, when they actually do have the disease). To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to (1-specificity), the ROC graph is sometimes called the sensitivity vs (1-specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold value is selected to provide an acceptable level of specificity and sensitivity usually determined by summing specificity values with sensitivity values. Consequently, the larger the calculated threshold value the greater the predicative power of the specific assay measurement under analysis.

In this context, "diseased" is meant to refer to a population having one characteristic (i.e., for example, the presence of a disease or condition or the occurrence of some outcome) and "nondiseased" population lacking the same characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.

In addition to threshold value comparisons, other methods for correlating assay measurements to a patient classification (i.e., for example, occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include, but are not limited to, decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject or patient belongs to one classification out of a plurality of classifications.

Multiple thresholds may also be used to assess renal status in a subject and/or patient. For example, a multiple thresholding method may combine a "first" subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., with a "second" subpopulation which is not so predisposed into a single group. This combination group is then subdivided into three or more equal parts (i.e., for example, tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile embodiment, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.

2. Specificity and Sensitivity

55

In some embodiments, a measured concentration of one or more renal biomarkers, or a composite of such biomarkers, may be treated as continuous variables. For example, any particular biomarker concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. Alternatively, a threshold value can provide an acceptable level of specificity and sensitivity in separating a population of subjects into "bins" such as a "first" subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a "second" subpopulation which is not so predisposed.

28

In one embodiment, a threshold value is selected to separate a first and a second population by one or more of the following measures of test accuracy:

- i) an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least 5 about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; 10
- ii) a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and 20 most preferably greater than about 0.95;
- iii) a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, erably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and 30 most preferably greater than about 0.95;
- iv) at least about 75% sensitivity, combined with at least about 75% specificity; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least about 2, more preferably at least about 3, still 35 more preferably at least about 5, and most preferably at least about 10; or
- v) a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 40 0.3, and most preferably less than or equal to about 0.1.

Various measures of test accuracy have been reported and used to determine the effectiveness of a given biomarker. Fischer et al., Intensive Care Med. 29:1043-1051 (2003). These accuracy measures include, but are not limited to, sensitivity and specificity, predictive values, likelihood 45 ratios, diagnostic odds ratios, and AUC ROC values. For example, AUC ROC values are equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. Consequently, an AUC ROC value may be thought of as equivalent to the 50 Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.

As discussed above, suitable tests may exhibit one or 55 more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, 60 preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more 65 preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding speci-

ficity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1.

G. Conventional Renal Diagnostics

As noted above, the terms "acute renal (or kidney) injury" with a corresponding specificity greater than 0.2, pref- 25 and "acute renal (or kidney) failure" as used herein are generally defined, in part, in terms of changes in serum creatinine from a baseline value. Most conventional definitions of ARF have common elements, including but not limited to the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR.

1. Glomerular Filtration Rate and Creatinine

Glomerular filtration rate (GFR) is generally definded as the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min:

By normalizing the GFR to the body surface area, a GFR of approximately 75-100 ml/min per 1.73 m² can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.

There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.

Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (UCr), urine flow rate (V), and creatinine's plasma concentration (PCr) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (UCr×V) divided by its plasma concentration. This is commonly represented mathematically as:

$$C_{Cr} = \frac{U_{Cr} \times V}{P_{Cr}}$$

Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:

$$C_{Cr} = \frac{U_{Cr} \times 24 \text{-hour volume}}{P_{Cr} \times 24 \times 60 \text{ mins}}$$

To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m². While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:

$$C_{Cr-corrected} = \frac{C_{Cr} \times 1.73}{BSA}$$

The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by 25monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is 30 readily and easily measured and it is specific for renal function.

For purposes of determining urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h 35 output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, some have assumed an average patient weight of 70 kg, wherein patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure). Bagshaw et al., *Nephrol. Dial. Transplant.* 23:1203-1210 (2008).

2. Treatment Regimen Selection

Once a renal diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, with- 45 drawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. Various appropriate treatments for 50 numerous diseases have been previously discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N J, 1999. In addition, since the methods and compositions described 55 herein provide prognostic information, the renal biomarkers of the present invention may be used to monitor a course of treatment. For example, an improved prognostic state or a worsened prognostic state may indicate that a particular treatment is or is not efficacious. 60

IV. Antibodies

Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term "specifically binds" is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to ⁶⁵ any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody "specifically binds" if its

affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In some embodiments, antibodies bind with affinities of at least about 10^7 M^{-1} , and preferably between about 10^8 M^{-1} to about 10^9 M^{-1} to about 10^{10} M^{-1} .

Affinity may be calculated as $K_{d}=k_{off}/k_{on}$ (k_{off} is the dissociation rate constant, K_{on} is the association rate constant and Kd is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: r/c=K(n-r): where r=moles of bound ligand/mole of receptor at equilibrium; c=free ligand concentration at equilibrium; K=equilibrium association constant; and n=number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., *J. Immunoassay* 12:425-443 (1991); and Nelson et al., *Com-*²⁵ put. Methods Programs Biomed. 27: 65-68 (1988).

Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g., Cwirla et al., Proc. Nati. Acad. Sci. USA 87: 6378-6382 (1990); Devlin et al., Science 249:404-406 (1990); Scott et al., Science 249: 386-388 (1990); and Ladner et al., U.S. Pat. No. 5,571,698 (all references herein incorporated by reference). A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.

Antibodies generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.

Antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the

50

55

development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody 5 pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.

V. Kits

In some embodiments, the present invention also contemplates devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the 15 described threshold comparisons.

In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.

In some embodiments, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test 30 sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, 35 or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most 40 preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling 45 encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.

EXPERIMENTAL

Example I

BioMaRK Data Collection Method

Patients and Study Design

BioMaRK was an observational cohort study conducted as an ancillary study to the Veterans Affairs/National Institutes of Health (VA/NIH) Acute Renal Failure Trial Network study (ATN study). The ATN study was a multicenter, prospective trial of two strategies for renal replacement therapy in critically ill patients with acute kidney injury. Coca et al., "Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review" *Kidney Int*, 73:1008-1016 (2008). Adult patients (18 years or older) with AKI and requiring renal-replacement therapy (RRT), as well as failure of one or more non-renal organ systems or sepsis were eligible. As a sub-study to the ATN study, 109

patients were enrolled at The University of Pittsburgh Medical Center, The VA Pittsburgh Healthcare System, The Cleveland Clinical Foundation, The University of Texas Health Science Center at Houston, and Washington University Medical Center to undergo serial blood and urine sampling. Incomplete data including unavailability of urine samples precluded inclusion of 33 subjects; consequently the remaining 76 formed the analysis cohort. Approval from the Institutional Review Boards was received from the University of Pittsburgh and all participating sites.

Data Collection/Laboratory Measurements

Medical records of study participants were prospectively reviewed to retrieve hospitalization data including baseline demographic characteristics, serial renal function, daily urine volume, and severity of illness scores. The presence of sepsis was defined by international consensus criteria. Levy et al., "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference" *Crit Care Med*, 31:1250-1256 (2003). Recovery of renal function was defined by survival and dialysis independence at Day 60 post AKI. For purposes of primary analysis, partial recovery (i.e. failure to return to baseline renal function but free of dialysis) was included in the recovery group. Similarly, all deaths were included in the non-recovery group.

Fresh urine samples were obtained on Days 1, 7, and 14 post AKI Immediately upon obtaining a well-mixed 30 ml sample, a protease inhibitor tablet (Roche Diagnostics Corporation, IN, USA) was added. After processing, the sample was frozen (at -80° C.) until analyzed. Samples were assayed in duplicate, and data were analyzed using Bio-Rad Bio-Plex Manager Software (version 4.1). Urine creatinine concentrations were measured using a non-enzymatic assay (DICT-500, BioAssay Systems, CA, USA).

Example II

Proteomics Analysis

Urine collected in accordance with Example I from fourteen (14) patients with severe AKI was evaluated with an unbiased proteomics discovery platform.

Data collected from seven (7) patients that did not recover renal function after AM was compared to data collected from seven (7) patients that did recover renal function after AKI. The two groups were matched for age (e.g., +/-5 yrs) and gender.

The data presented herein show that approximately thirty (30) proteins were differentially expressed between the Recovery Group and the Non-Recovery Group. A preliminary analysis has categorized these proteins into groups including, but not limited to:

- Ferritin, alpha and beta globin, or catalase that may be involved in providing protection from reactive oxygen species
- 2. Complement factor H or complement component 4 BP that may be involved in regulation of complement activation
- 3. Olfactomedin-4, leucine rich alpha-2 glycoprotein or ring finger protein 167 that may be involved in cell survival and proliferation.
- 4. Inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, (N-acylsphingosine aminohydrolase and saposin) that may be involved in basement membrane, matrix proteins or sphingolipid turnover.

Although it is not necessary to understand the mechanism of an invention, it is believed that the differential expression of proteins categorized in Group 3 and Group 4 might be directly involved in renal recovery because of their involvement with cell proliferation and/or rebuilding of the basement membrane.

4

LENGTHY TABLES

The patent contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US09551720B2). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

SEQUENCE LISTING

The patent contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US09551720B2). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

We claim:

1. A method of treating, comprising:

- a) collecting at least one urine sample from a patient within fourteen days of exhibiting an acute renal injury, wherein said patient is asymptomatic of a renal disease;
- b) expressing a plurality of renal injury protein biomarker nucleic acids from said at least one urine sample with 30 a proteomics platform to create a signature expression profile, said profile comprising a renal injury protein biomarker panel;
- c) detecting a plurality of overexpressed renal injury protein biomarkers and a plurality of underexpressed 35 renal injury protein biomarkers from said renal injury biomarker panel when compared to a renal recovery group comprising individuals without an acute renal injury,
 - wherein said plurality of overexpressed renal injury 40 protein biomarkers are selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform and annexin A2, 45 and
 - wherein said underexpressed renal injury protein biomarkers are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, 50 fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger 55 protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, 60 fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, and uromodulin precursor;
- d) creating a probability value of non-recovery for said patient from said acute renal injury by a combination of receiver operated characteristic area under the curve

determinations for said plurality of detected overexpressed renal injury biomarkers and said plurality of detected underexpressed renal injury biomarkers as compared to a plurality of diagnostic threshold values, wherein said acute renal injury recovery is determined by an improved renal function;

e) treating said patient during the development of said renal disease with a treatment regimen selected from the group consisting of: i) said treatment regimen comprising adverse effects when said probability value of non-recovery from said acute renal injury is greater than 50%, and ii) said treatment regimen without adverse effects when said probability value of nonrecovery from said acute renal injury is less than 50%.

2. The method of claim **1**, wherein said probability value of non-recovery from said acute renal injury is less than 25%.

3. The method of claim 1, wherein said treatment regimen is selected from the group consisting of initiating renal replacement therapy, withdrawing kidney damaging compounds, kidney transplantation, delaying or avoiding kidney damaging procedures and modifying diuretic administration.

4. The method of claim **1**, wherein said plurality of overexpressed renal injury biomarkers are between approximately 1.5 fold-2.5 fold higher in comparison to an expected value from said renal recovery group.

5. The method of claim **1**, wherein said plurality of underexpressed renal injury biomarkers are between approximately 1.5 fold and 2.0 fold lower in comparison to an expected value from a renal recovery group.

6. The method of claim **1**, wherein said probability value of non-recovery from said acute renal injury is less than 10%.

7. The method of claim 1, wherein said probability value of non-recovery from said acute renal injury is greater than 75%.

8. The method of claim **1**, wherein said probability value of non-recovery from said acute renal injury is greater than 90%.

* * * * *

25 nt